



HMA

The Intersection of HIV and Substance Use: Enhancing the Care Continuum with Evidence-Based Practices

Training Series: Session 3
November 19, 2025

Copyright © 2025 Health Management Associates, Inc. All rights reserved. The content of this presentation is property of HMA and CREDIBLE, Inc. Health Management Associates, Inc. and CREDIBLE, Inc. are the information of the intellectual property. Do not use, publish or redistribute without written permission.

UTILIZING ZOOM

- » Ensure your audio is linked to your Zoom participant ID.
- » If you joined the audio by computer_microphone and speaker, then you're all set.
- » If you joined the audio with a phone and did not enter your unique participant ID then enter #<your participant ID># on your phone now.

Note: Your unique participant ID can be found by clicking on the lower left corner of your Zoom screen where it says, 'Join Audio' and your Participant ID will appear.

- » Ensure you are on MUTE and your camera is ON. On the bottom left corner of your screen, you will see a red line through the microphone



- » Your participation throughout today via chat is appreciated!

» Locate the chat box. On the bottom middle of your screen, click on the chat icon. This will open the "Zoom Group Chat" pane on the right side of your screen. You will see messages throughout the webinar on there. When prompted by the presenters, type in your answers or questions there.

© 2025 Health Management Associates, Inc. All Rights Reserved.

2

UTILIZING ZOOM

- » If you would like to enable closed captions during this session, please follow the steps below.
 - » On the Zoom room toolbar, tap the **Captions**  icon.
 - » You may need to tap the **More**  icon first to see the option.
 - » Ensure that the **Show Captions** toggle  is enabled.
- » If you have any issues or questions about this feature, message Gabriel Velazquez in the chat and he can assist you.
 

© 2025 Health Management Associates, Inc. All Rights Reserved.

3

HOUSEKEEPING

Today is Session 3

Please complete the evaluation for the webinar that will be sent out via email after each session.

You will be receiving a PDF of today's presentation.

This session is being recorded.

Follow-up questions?

Contact Gabriel Velazquez:
gvelazquez@healthmanagement.com

© 2025 Health Management Associates, Inc. All Rights Reserved.

4

CEUS ELIGIBILITY AND DISTRIBUTION

» This series is eligible for CEUs

» These activities have been approved for CEUs by the Minnesota Board of Behavioral Health and Therapy for a total of 12 hours (if fully attended) for LADCs and LPC/LPCCs

» To qualify for CEUs, you are required to

1. Complete the pre-training quiz
2. Be in attendance for the entire session
3. Complete the accompanying evaluation survey for each session attended
4. Complete the post-training quiz

» CEU certificates will be issued approximately 1-2 weeks AFTER the completion of the training.

» Any follow-up questions, please contact Gabriel Velazquez: gvelazquez@healthmanagement.com

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

5

LAND ACKNOWLEDGMENT



Every community owes its existence and vitality to generations from around the world who have contributed their hopes, dreams, and energy to making the history that led to this moment. Some were brought here against their will, some were drawn to leave their distant homes in hope of a better life, and some have lived on this land for more generations than can be counted. Truth and acknowledgment are critical to building mutual respect and connection across all barriers of heritage and difference.

We begin this effort to acknowledge what is buried by honoring the truth. **We are standing on the ancestral lands of the Dakota people. We want to acknowledge the Dakota, the Ojibwe (pronounced ow-jeeb-way), the Ho Chunk, and the other nations of people who also call this place home.** We pay respects to their elders past and present.

Please take a moment to consider the treaties made by the Tribal nations that entitle non-Native people to live and work on traditional Native lands. Consider the many legacies of violence, displacement, migration, and settlement that bring us together here today. Please join us in uncovering such truths at any and all public events.*

*This is the acknowledgment given in the USDAC Honor Native Land Guide – edited to reflect this space by Shannon Geshick, MTAG, Executive Director Minnesota Indian Affairs Council

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

7

ACKNOWLEDGMENTS

We would also like to thank our community partners for their support in developing this curriculum.



Rain Project



the Aliveness project



Indigenous Peoples Task Force



RAN
RURAL AIDS ACTION NETWORK
Providing Care, Service, and Support



First American Community Center

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

6

TODAY'S PRESENTERS



Charles Robbins, MBA
(he/him/his)

Principal
Health Management Associates



**Anika Alvarno, MD, MS,
FACP, DFASAM**
(she/her/hers)

Physician Principal
Health Management Associates

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

8

TIME FOR A POLL

Who is in the Zoom room today?

- » Please select your role or discipline in the pop-up poll
 - » Administration / Programs
 - » Counselor / Therapist / LADC
 - » Case Manager
 - » Harm Reduction / Peer Recovery
 - » Nurse / Physician
 - » Probation Officer / Justice Involved
 - » Sexual Health / Community Health Worker
 - » Social Worker / Child Welfare / Housing
 - » Workforce / Skills Development
 - » If "other" type in chat

©2020 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
9

AGENDA FOR WEBINAR SERIES

Session	Topics
#1 WEDNESDAY, NOVEMBER 5 12:00 pm to 3:00 pm	<input type="checkbox"/> Understanding HIV <input type="checkbox"/> HIV Testing, Treatment and Prevention <input type="checkbox"/> The Science of Addiction <input type="checkbox"/> Screening and Assessment
#2 WEDNESDAY, NOVEMBER 12 12:00 pm to 3:00 pm	<input type="checkbox"/> Ethical and Legal Issues <input type="checkbox"/> Funding and Policy Considerations <input type="checkbox"/> HIV Risk Reduction <input type="checkbox"/> SUD Harm Reduction <input type="checkbox"/> HIV and Stigma <input type="checkbox"/> Motivational Interviewing
#3 WEDNESDAY, NOVEMBER 19 12:00 pm to 3:00 pm	<input type="checkbox"/> Working with Persons Involved in the Legal System <input type="checkbox"/> Substance Use Disorder Treatment with Medications <input type="checkbox"/> Mental Health Treatment and Counseling <input type="checkbox"/> Stimulant Use <input type="checkbox"/> Chem Sex
#4 WEDNESDAY, DECEMBER 3 12:00 pm to 3:00 pm	<input type="checkbox"/> Cultural, Racial and Sexual Identities <input type="checkbox"/> Pregnancy and HIV, SUD/OUD <input type="checkbox"/> Accessing, Obtaining, and Integrating Services for Individuals with HIV and SUD in Minnesota

©2020 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
10

WORKING WITH LEGALLY-INVOLVED INDIVIDUALS AND MEDICATION FOR ADDICTION TREATMENT

LEARNING OBJECTIVES:

Describe the importance of substance use disorder treatment for those who are legally involved

List 3 actions to take to ensure continuity of care for clients upon release from incarceration

Compare and contrast FDA approved medications for Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and opioid reversal

©2020 Health Management Associates, Inc. All Rights Reserved.
12

WHAT IS THE DIFFERENCE?

Jail


- Awaiting Trial or
- Short duration of sentence
- Run by County Sheriff or local government

Prison


- Convicted of a crime
- Long duration of sentence
- Run by state or federal governments
- More education and rehabilitative programs

© 2020 Health Management Associates, Inc. All Rights Reserved.


13







14



15



16



BURDEN OF SUBSTANCE USE DISORDER (SUD) IN CARCERAL SETTINGS

- » 63% of people in jail and 58% in prison have a SUD.*
- » Historically jails withdrew people from medication for addiction treatment.**
- » Outcomes are much better if continued on treatment.**
- » 77% of deaths within 2 weeks of release are related to overdose.
- » This can be decreased by 60-80% with access to medication ***

* <https://www.samhsa.gov/criminal-juvenile-justice/about>
** <https://www.ojp.gov/policy-reports/2007>
*** <https://www.ojp.gov/policy-reports/2023>

GUIDELINES FOR MANAGING SUBSTANCE WITHDRAWAL IN JAILS
A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals
June 2023
BJA | NIC
NATIONAL COMMISSION ON CORRECTIONAL HEALTH CARE

JAIL GUIDELINES FOR THE MEDICAL TREATMENT OF SUBSTANCE USE DISORDERS 2025
Find this free resource online at nic.samhsa.gov/toolkit/nat
Issued by JAIL | NIC

21

© 2025 Health Management Associates, Inc. All Rights Reserved.
GUIDELINES FOR MANAGING SUBSTANCE WITHDRAWAL IN JAILS: A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals. National Commission on Correctional Healthcare. (2023) Jail guidelines for the medical treatment of substance use disorders 2025.

HEALTH MANAGEMENT ASSOCIATES

SERVICES PROVIDED IN CARCERAL SETTINGS

- » Screening for medical, mental health, substance use disorders and dental issues
- » Assessments for medical, mental health, substance use disorders and dental issues
- » Acute and chronic treatment of these conditions, including
 - » Overdose reversal & overdose prevention education
 - » Withdrawal management
 - » Medications
 - » Counseling
 - » Preventative care
 - » Linkage to care in the community
 - » Naloxone upon release

22

TRANSITION OF CARE

- » Transition of Care – The movement of a patient from one setting of care to another.
- » Actions to ensure continuity of care
 - » Provide overdose reversal agent on release
 - » Provide medication until first community appointment
 - » Strive for a warm handoff to community provider
- » Challenges in jails and beyond
 - » No clear discharge date/time
 - » Release not correlated to clinical condition
 - » Housing options frequently suboptimal

Source: <https://store.samhsa.gov/catalog/file/d7/priv/sma16-4998.pdf>
<https://www.ncjrh.org/policy-reports/2024-05/1/2/diversion-10-3-in-prison-use-2-borders-3-8-25.pdf>

Source: <https://store.samhsa.gov/sites/default/files/d7/priv/sma16-4998.pdf>

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES



COMMUNITY OPPORTUNITIES TO MINIMIZE INCARCERATION

- » Early identification of individuals with mental and substance use disorders at all points of contact with the legal system
- » Diversion from the legal system to community-based treatment
- » Engaging law enforcement, first responders, and crisis management teams, court personnel, and community treatment providers in diversion strategies that meet both clinical and public safety needs
- » Use of validated screening and assessment tools

24

COMMUNITY OPPORTUNITIES TO MINIMIZE INCARCERATION CONT.

- » Training and technical assistance for law enforcement, judges, probation officers, child welfare staff on behavioral health issues; training for behavioral health providers on criminogenic risk and the adult and juvenile legal system.
- » Provision of services and supports to enable successful reentry
 - » Identification
 - » Insurance
 - » Transportation
 - » Housing
 - » Education, vocational training, resume writing, interview skills and clothing
- » Equitable opportunities for diversion and community services.
 - » Must track data
- » Collaboration to better serve those involved with behavioral health and legal systems.

Source: <https://store.samhsa.gov/sites/default/files/d7/priv/sma16-4998.pdf>

HEALTH MANAGEMENT ASSOCIATES

25

TIME FOR A POLL

Statement: My organization has an active working process to identify and provide a soft landing into the community for patients with complex care management needs related to addiction and HIV upon release from carceral settings.

- A. Yes
- B. No
- C. I Am Not Sure

HEALTH MANAGEMENT ASSOCIATES

26

INTERVENTIONS TO REDUCE HARMS RELATED TO DRUG USE AMONG PEOPLE WHO EXPERIENCE INCARCERATION

- » 126 studies reviewed of 18 different interventions
 - » Receiving opioid agonist treatment in first 4 weeks following release reduces risk of death in community
 - » More likely to engage in treatment and take agonist treatment if it was prescribed while in prison
 - » Receiving opioid agonist treatment in prison reduces risk of death in prison
 - » Therapeutic communities in prison reduce rearrest

Macdonald C, Macpherson G, Leppan O, Tran LT, Cunningham EB, Hajarizadeh B, Grebely J, Farrell M, Altice FL, Degenhardt L. Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis. *Lancet Public Health*. 2024 Sep;9(9):e684-e699. doi: 10.1016/S2468-2667(24)00160-9. PMID: 39214637.

HEALTH MANAGEMENT ASSOCIATES

27

COURT / PROFESSIONAL MANDATED TREATMENT

- » Outcomes are variable but generally not worse than non-mandated treatment.
- » Important issues to consider
 - » This data only reviews court mandates for criminal behavior, not civil commitment for SUD and data is significantly influenced by lack of evidence-based treatments offered in programs reviewed.
 - » Ensure equitable access to diversion from incarceration
 - » Only mandate people to treatment who have a SUD
 - » Ensure people enter the appropriate level of care- individualized treatment planning, not a preference for residential treatment
 - » Ensure equitable access to medication for addiction treatment

Drug Policy Alliance. (2024). The Drug Treatment Debate. Retrieved on 7.23.25 from https://drugpolicy.org/wp-content/uploads/2024/08/TheDrugTreatmentDebate_10.30.24-Interactive.pdf
 Hachef H, Vogel T, Huber CG. (2019). Mandated Treatment and Its Impact on Therapeutic Process and Outcome Factors. *Front Psychiatry*. 10:219.
 Werb D, et al. The effectiveness of compulsory drug treatment: A systematic review. *Int J Drug Policy*. 2016 Feb;28:1-9.
 White, S. What to Know About Mandated Treatment Programs. Retrieved 7.23.25 from <https://opioidprinciples.jhsph.edu/what-to-know-about-mandated-treatment-programs/>
 Pilavros A, et al. (2020). Coercion into addiction treatment and subsequent substance use patterns among people who use illicit drugs in Vancouver, Canada. *Addiction*;115(1):97-106.
 Farabee, D et al. (1998). Effectiveness of coerced treatment of drug abusing offenders. *Federal Probation* 62:1.

28

SUBSTANCE USE DISORDER TREATMENT WITH MEDICATIONS

WHAT IS SUBSTANCE USE DISORDER TREATMENT WITH MEDICATIONS?


- » The use of FDA-approved prescription medications, usually in combination with counseling and behavioral therapies, to provide a whole-person approach to the treatment of substance use disorders (SUD).
- » When discussing medication for opioid use disorder this is frequently referred to as Medications for Opioid Use Disorder (MOUD).
- » MOUD has proven clinically effective to alleviate symptoms of withdrawal & reduce cravings. MOUD maintenance has been proven to cut overdose rates in half and decrease rates of HIV and hepatitis C transmission.
- » Research shows that a combination of MOUD and behavioral therapies is a successful method to treat OUD.

HEALTH MANAGEMENT ASSOCIATES


30

WHICH SUBSTANCE USE DISORDERS ARE TREATED WITH MEDICATIONS?

Substance Use Disorder's with FDA Approved Medications



No FDA Approved Medications
Medications Not Part of Best Practices



©2020 Health Management Associates, Inc. All Rights Reserved.

31

WHY IS MEDICATION FOR OPIOID USE DISORDER IMPORTANT?

Treat Withdrawal

- Muscle pain, dilated pupils, nausea, diarrhea, abdominal cramping, piloerection
- Lasts 14 days
- Methadone or buprenorphine are recommended over abrupt cessation due to risk of return to use, overdose (OD) & death

Sources: ASAM. (2020) National Practice Guidelines for the Treatment of OUD. Mattick, RP & Hall W (1996) Lancet 347: 8994, 97-100. Mattick, RP et al. (2008) Cochrane Systematic Review. Mattick, RP, et al. (2009) Cochrane Systematic Review. Lohman, P et al. (2009) Cochrane Systematic Review. Krupitsky et al. (2011) Lancet 377, 1506-13. Kukko et al. (2003) Lancet 361(9358):662-8. Rich, JD, et al. (2015) Lancet; Heimer, R (2024) Drug and Alcohol Dependence.

Address Dopamine Depletion

- Reward/motivation pathway abnormalities persists for months after people stop using
- Treated with methadone or buprenorphine

Treat OUD/Achieve Results

- Without medication 85% return to opioid use within 1 year and results in more deaths than not treatment
- MOUD decreases
 - Use
 - Craving
 - Complications from IVDU
 - Criminal behavior
- MOUD increases retention in treatment

HEALTH MANAGEMENT ASSOCIATES

32

FDA APPROVED MEDICATION FOR OUD

Agonist Treatment
(turns on the receptor):

- Methadone- approved for cough in 1940s, for OUD 1972
- Buprenorphine (Suboxone™, Subutex™, Sublocade™ and Brixadi™)- approved in 1981 for pain; oral approved for OUD 2002, patch, implants & injection later

Antagonist Treatment (blocks receptor from turning on):

- Naltrexone (Revia™)- oral approved 1984; injectable (Vivitrol™) 2006 for AUD, 2010 for OUD
- Naloxone- approved 1971, autoinjector 2014, nasal spray (Narcan™) 2015
- Nalmefene (Opree™) - injectable approved 1995; nasal spray approved 2023

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

33

HOW DO THE FDA APPROVED MEDICATIONS WORK?


Agonist Treatment

Antagonist Treatment

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

34



METHADONE: WHAT AND FOR WHOM?

- >> Mu opioid receptor full agonist
 - >> No "ceiling effect"
- >> Can start prior to being in withdrawal
- >> Reaching a therapeutic dose takes time
 - >><60 mg/d is not therapeutic
 - >> Typical dose 60-120 mg/d
 - >> Increased frequency and daily dose required during pregnancy
- >> Several drug-drug interactions
- >> Illegal to write prescription for methadone to treat OUD unless:
 - >>Opioid Treatment Program (OTP)
 - >>Covering a gap of no more than 3 days
 - >>Patient is in a DEA licensed clinic or hospital with another condition

Patients with a more severe OUD, such as injecting opioids

Patients who have not reached treatment goals with other MOUD

Patients who would benefit from the closest follow up at NTP

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

36

METHADONE: GENERAL FEDERAL REGULATIONS

Delivered via observed dosing 	Once patient is stable, can be given take-home doses (varies by state) 	
Highly monitored in a Narcotics or Opioid Treatment Program setting (NTP/OTP) 	Requirements for onsite services including therapy, toxicology... 	

<https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder>

© 2024 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

37

METHADONE: EFFICACY DATA

- » Methadone resulted in 33% fewer opioid positive toxicology tests compared to those receiving no medication* when everyone receives psychosocial treatment
- » 4.4x more likely to stay in treatment *
- » Reduced crime *
- » Reduced infectious disease*
- » Reduced death**

Source:
* Mattick 2009 Cochrane Review
** Wakeman 2020 JAMA Open Network

© 2024 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES



BUPRENORPHINE: WHAT AND FOR WHOM?

- » Partial mu opioid agonist with ceiling effect
 - » Doses >32 mg don't cause greater respiratory effects
 - » Available sublingually alone or in combination w/haloxone and as a long acting- weekly or monthly injections
- » Greater binding affinity than full agonists
 - » Start buprenorphine when client in moderate withdrawal (to avoid causing precipitated withdrawal)
 - » Other opioids are not as effective when buprenorphine is present
 - » Typical dose is 16-32 mg/d
 - » Increased frequency and daily dose required during pregnancy
- » Fewer drug-drug interactions than methadone

Opioid use disorder or withdrawal

Patient wants agonist treatment

Mattick, R. P., et al. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *The Cochrane Database of Systematic Reviews*, 2014(2), CD002207. Weimer, M. B., et al. (2023). ASAM clinical considerations: Buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids. *Journal of Addiction Medicine*, 17(6), 632-639. Bureau of Justice Assistance. (June 2023). *Guidelines for managing substance withdrawal in jails*. U.S. Department of Justice.

© 2024 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

39

BUPRENORPHINE EFFICACY

- » Rate of return to opioid use for persons taking placebo was 100% vs 25% for persons taking buprenorphine
- » If taking ≥ 16 mg buprenorphine you are 1.82 times more likely to stay in treatment than if on placebo
- » Decreased crime, infectious disease and death*

Source:
NIDA Medications to Treat Opioid Use Disorder Research Report Updated December 2021
Mattick 2014 Cochrane Review
* Wakeman 2020 JAMA Open Network

© 2024 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES



40

NALTREXONE: WHAT AND FOR WHOM?

- » Mu opioid antagonist with high, competitive binding affinity
- » Does not treat withdrawal or low dopamine levels
- » Must be opioid free x 14 days before starting and/or have completed withdrawal if recently using
- » No evidence of decreased mortality

Patients with a high degree of motivation (dopamine)

Patients with a history of OUD and Alcohol Use Disorder (AUD): FDA approved for both

Patients who did not reach treatment goals with methadone or buprenorphine

Can be useful for occasional use or after discontinuation of methadone or buprenorphine

Source: Larochelle, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. *Annals of Internal Medicine*. 169(3) (2018):137-45. Wakeman, SE, et. al. (2020) Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. *JAMA Open Network*. 3 (2).

©2020 Health Management Associates, Inc. All Rights Reserved.

41

NALTREXONE: GENERAL REGULATIONS

No Federal regulations inhibit the use

Not all BH clinics have RN to give injections

Multiple formulations:

- Pills at 25mg and 50 mg (50-100 mg for AUD)
- Long acting injectable 380mg (28-30 days) for AUD and OUD

©2020 Health Management Associates, Inc. All Rights Reserved.

42

NALTREXONE: EFFICACY DATA

- » Extended Release (XR) Naltrexone 90% opioid abstinent toxicology tests vs. 35% placebo*
 - » Decreased incarceration**
- » XR Naltrexone vs usual care in HIV clinic***
- » Fewer days of opioid use for those on XR Naltrexone



This Photo by Unknown Author is licensed under CC BY

Source:
*Krupitsky 2011 Lancet
**Minozzi 2011 Cochrane Review
***Korthuis 2022

©2020 Health Management Associates, Inc. All Rights Reserved.

43

OD REVERSAL IS HARM REDUCTION

- » Mu opioid antagonists: naloxone & nalmefene
- » Shorter half-life & more rapid onset of action than naltrexone
- » High affinity, competitive binding & displaces agonists
- » Intranasal or intramuscular by bystander
- » May require more than one dose
- » Opioids have longer half-life than naloxone
- » Saves lives; no evidence for increasing drug use
- » Good Samaritan law in MN
- » MN no age restriction:
https://www.health.state.mn.us/communities/opioids/documents/naloxonestandingorder.pdf
- » Available over the counter

In 2019, 77.3% of 33,084 opioid-involved overdose deaths across 37 states + the District of Columbia had no evidence of naloxone administration.

Source: Quen, et. al. (2022) Naloxone administration among opioid-involved overdose deaths in 38 United States jurisdictions in the State Unintentional Drug Overdose Reporting System. 2019. Drug and Alcohol Dependence. 268: 10847

With additional substances within our illicit drug supply it is imperative that we remember to provide breaths/ oxygen between doses of naloxone.

Source: Durkian C, et al. American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Anesthesiology, Thrombosis and Vascular Disease; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Opioid-Associated Out-of-Hospital Drug Arrests and Deaths: A Call for Action. American Heart Association Council on Cardiopulmonary, Critical Care and Public Response. A Scientific Statement From the American Heart Association. Circulation. 2021 Apr 20;143(16):e836-e870. doi: 10.1161/CIR.0000000000000958. print 2021 Mar 8.

©2020 Health Management Associates, Inc. All Rights Reserved.

44

NALOXONE DISTRIBUTORS IN MINNESOTA

» In response to the opioid crisis in Minnesota, the Minnesota Department of Health (MDH) developed KnowTheDangers.com to provide clear, fact-based information, access to recovery programs, and essential harm reduction resources.

» One key resource on the site is the Naloxone Finder, which helps locate naloxone distribution sites.

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

45



NALOXONE RESOURCES

- » <https://www.health.state.mn.us/communities/opioids/opioid-dashboard/resources.html#naloxone>
- » University of Minnesota Naloxone Resources <https://www.pharmacy.umn.edu/degrees-and-programs/continuing-pharmacy-education/continuing-education-courses/naloxone>
- » Naloxone overdose training and kits free of charge. The following community-based organizations provide Naloxone overdose training and kits free of charge:
 - » [Steve Rummel HOPE Network](#)—Call 952-943-3937 or sign up for training from the [Steve Rummel HOPE Network](#).
 - » [Rural AIDS Action Network \(RAAN\)](#)—Call 320-257-3036.
 - » [Red Door Clinic](#)—Call 612-543-5555.
 - » [Indigenous Peoples Task Force](#)—Call 612-870-1723.
 - » [Lutheran Social Services](#)—Call 800-582-5260.
- » <https://knowthedangers.com/>

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

46

TIME FOR A POLL

Question:

Do you know if your organization is currently prescribing (or providing) or doing any training on naloxone?

A. Yes
B. No
C. I Don't Know

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

47

HOW LONG TO TREAT OUD?

- » Studies of all FDA approved meds for OUD indicate a risk of return to opioid use upon discontinuation of meds
- » **Year(s) post sobriety**, if changes to decrease likelihood of future substance use, stable in recovery and life and wants to discontinue
 - » Social Support that supports recovery
 - » Active in 12 step meetings or
 - » Active in Self-Management and Recovery Training (SMART) meetings
 - » Active in church
 - » Not living with people who are using
 - » Able to handle interpersonal conflicts without returning to use
 - » Avoid tapering during big life transitions such as leaving incarceration, pregnancy or delivery, moving across the country, changing jobs

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

48

HOW LONG SHOULD SOMEONE BE ON MEDICATION?

Long-term or indefinite treatment with medications for OUD is often needed to maintain outcomes

Discontinuing buprenorphine or methadone is usually only successful in about 15% of cases

Discontinuing medication without return to opioid use usually occurs, if at all, when people have been treated with MOUD for at least 3 years

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder, Mancher, M., & Leshner, A. I. (Eds.). (2019). Medications for opioid use disorder save lives. National Academies Press (US).

Nosyk, B., et al. (2012). Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. *Addiction* (Abingdon, England), 107(9), 1621–1629. <https://doi.org/10.1111/j.1360-0443.2012.03870.x>.

Substance Abuse and Mental Health Services Agency (SAMSHA) and the Office of the Surgeon General. (2018). Facing addiction in American: The Surgeon General's spotlight on opioids. https://www.hrsa.gov/sites/default/files/OC_SpotlightOnOpioids.pdf

49

© 2023 Health Management Associates, Inc. All Rights Reserved

REFERENCES: LEGAL SYSTEM-INVOLVED INDIVIDUALS & MOUD

- Bureau of Justice Assistance. (June 2023). Guidelines for managing substance withdrawal in jails. U.S. Department of Justice.
- Bureau of Justice Assistance. (2024). Census of Jails (COJ). Bureau of Justice Statistics. bjs.ojp.gov/data-collection/census-jails-coj. Accessed 17 Jan. 2024.
- Dieruffian, C., et al.; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Council on Clinical Cardiology. Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association. *Circulation*. 2021 Apr 20;143(16):e636-e670. doi: 10.1161/CIR.0000000000000958. Epub 2021 Mar 8.
- Farabee, D. et al. (1998). Effectiveness of coerced treatment of drug abusing offenders. *Journal of Clinical Psychiatry*. 59(12), 721-725. doi: 10.1017/jcp.1998.11100.
- Green, T. C. et al. (2018). Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. *JAMA Psychiatry*, 75(4), 405–407. <https://doi.org/10.1001/jamapsychiatry.2017.4614>
- Healthresearchfunding.org(2019) <https://healthresearchfunding.org/24-opiate-addiction-recovery-statistics/> 24 Shocking Opiate Addiction Recovery Statistics
- Heimer, R, Black AC, Lin H, Grais LE, Fiellin DA, Howell BA, Hawk K, D'Onofrio G, Becker WC. Receipt of opioid use disorder treatments prior to fatal overdoses and comparison to no treatment in Connecticut, 2016-17. *Drug Alcohol Depend*. 2024 Jan 1;254:111040. doi: 10.1016/j.drugalcdep.2023.111040. Epub 2023 Nov 28. PMID: 38043226; PMCID: PMC10872282.
- <https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder>
- Initiative, P. P. (n.d.). Minnesota incarceration pie chart 2023. [www.prisonpolicy.org](https://www.prisonpolicy.org/graphs/correctional_control2023/MN_incarceration_2023.html). Retrieved November 15, 2023, from https://www.prisonpolicy.org/graphs/correctional_control2023/MN_incarceration_2023.html
- Initiative, P. P. (n.d.). Minnesota profile. [www.prisonpolicy.org](https://www.prisonpolicy.org/profiles/MN.html). <https://www.prisonpolicy.org/profiles/MN.html>
- Initiative, P. P. (n.d.). New data on HIV in prisons during the COVID-19 pandemic underscore links between HIV and incarceration. [www.prisonpolicy.org](https://www.prisonpolicy.org/blog/2023/06/01/hiv_in_prisons). Retrieved November 15, 2023, from https://www.prisonpolicy.org/blog/2023/06/01/hiv_in_prisons
- Kakko et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet* (2003) 361(9358):662-8.
- Korthuis PT, et al. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. *Addiction*. 2022 Jul;117(7):1961-1971. doi: 10.1111/add.15836. Epub 2022 Mar 2. PMID: 35129242; PMCID: PMC9314106.

© 2023 Health Management Associates, Inc. All Rights Reserved

50

REFERENCES: LEGAL SYSTEM-INVOLVED INDIVIDUALS & MOUD

- Kinlock, T. W., et al. (2007). A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. *Drug and Alcohol Dependence*, 91(2-3), 220–227.
- Krupitsky, et. al. Injectable extended-release naltrexone for opioid dependence: a double-blind placebo controlled, multicenter randomized trial. 2011; *Lancet* 377: 1506–13.
- Larocheille, et. al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. *Annals of Internal Medicine*. 169(3) (2018) 137-45.
- Lim S, et al. (2023) Association between Jail-Based Methadone or Buprenorphine Treatment for Opioid Use Disorder and Overdose Mortality after Release from New York City Jails 2011-17. *Addiction* (Abingdon, England), U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/36305669/.
- Matick, RP, et al. (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Systematic Review.
- Matick, RP, et al. (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Systematic Review.
- Macdonald C, Macpherson G, Leppan O, Tran LT, Cunningham EB, Hajriziadeh B, Grebely J, Farrell M, Aitcice FL, Degenhardt L. Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis. *Lancet Public Health*. 2024 Sep;9(9):e684-e699. doi: 10.1016/S2468-2667(24)00160-9. PMID: 39214637.
- Metzger DS et al., Human Immunodeficiency Virus Seroincidence Among Intravenous Drug Users In- and Out-of-Treatment: An 18-Month Prospective Follow-Up. *Journal of Acquired Immune Deficiency Syndromes* 6, no. 9 (1993): 1049–56. <http://www.ncbi.nlm.nih.gov/pubmed/8340896>.
- MINNESOTA DEPARTMENT OF CORRECTIONS. (n.d.). Retrieved November 15, 2023, from https://mn.gov/doc/assets/Adult%20Prison%20Population%20Summary%207-1-2023_tcm1089-589994.pdf
- Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database Syst Rev*. 2011;2011(4):CD001333. Published 2011 Apr 13. doi:10.1002/1465-1858.CD001333.pub4
- National Commission on Correctional Healthcare. (2025) Jail guidelines for the medical treatment of substance use disorders 2025.
- NIDA Medications to Treat Opioid Use Disorder Research Report. Updated December 2021.
- Pilarinos A, et al. (2020). Coercion into addiction treatment and subsequent substance use patterns among people who use illicit drugs in Vancouver, Canada. *Addiction*;115(1):97-106.
- *Principals of Drug Addiction Treatment: A Research Based Guide.* National Institute on Drug Abuse. Ed. NIDA International Program.

51

© 2023 Health Management Associates, Inc. All Rights Reserved

REFERENCES: LEGAL SYSTEM-INVOLVED INDIVIDUALS & MOUD

- Prison Policy Initiative. <https://www.prisonpolicy.org/profiles/MN.html>
- Quinn, et al. (2022). Naloxone administration among opioid-involved overdose deaths in 38 United States jurisdictions in the State Unintentional Drug Overdose Reporting System. 2019. *Drug and Alcohol Dependence*, 235, 109467.
- Rich, JD, et al. Continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomized, open-label trial. *Lancet* (2015) 386 (9991):350-359.
- Schwartz RP, et al. Opioid agonist treatment and heroin overdose deaths in Baltimore, Maryland, 1995-2009. *Am J Public Health*. 2013 May;103(5):917-22. doi: 10.2105/AJPH.2012.301049. Epub 2013 Mar 14. PMID: 23488511; PMCID: PMC3670653.
- Substance Abuse and Mental Health Services Administration. Guidelines for Successful Transition of People with Mental or Substance Use Disorders from Jail and Prison: Implementation Guide. (SMA)-16-4998. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2017.
- Substance Abuse Mental Health Services Agency. Medications for Opioids Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients and Families. Rockville MD SAMHSA Treatment Improvement Protocol (TIP) Series, No. 63 (2021).
- Substance Abuse Mental Health Services Agency (2024) About Criminal Justice and Juvenile Justice. <https://www.samhsa.gov/criminal-juvenile-justice/about>
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder. 2020 Focused Update. (2020) *J Addict Med*14(2S Suppl 1):1-91. doi: 10.1097/ADM.0000000000000633. Erratum in: *J Addict Med*. 2020 May/June;14(3):267. PMID: 32511106.
- Treatment Research Institute (TRI). Ed. "Cost Utilization Outcomes of Opioid Dependence Treatment" American Journal of Managed Care 2011.
- Tsui, JI, et al., "Associates of Opioid Agonist Therapy With Lower Incidence of Hepatitis C Virus Infection in Young Adult Injection Drug Users," *JAMA Internal Medicine* 174, no. 12 (2014): 1974–81. <http://archinte.jamanetwork.com/article.aspx?articleid=1918926>
- United States Department of Justice. Office of Justice Programs. Bureau of Justice Assistance. Guidelines For Managing Substance Withdrawal In Jails A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals. June 2023
- Wakeman, SE, et al. (2020) Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. *JAMA Open Network*. 3 (2).
- Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp BA, Ramsey KS. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids. *J Addict Med*. 2023 Nov-Dec;01;17(6):632-639. doi: 10.1097/ADM.0000000000001202. Epub 2023 Jul 28.
- www.druginserts.com

© 2023 Health Management Associates, Inc. All Rights Reserved

52

ALCOHOL

- Alcohol is the most used addictive substance.
- Alcohol-related deaths (worldwide)
 - 2.6 million alcohol-related deaths/year compared to .6 million drug-related deaths/year.
 - 4.7% of all deaths are related to alcohol consumption.
- Alcohol is the most common substance causing withdrawal related deaths in jails.

Sources

- Substance Abuse and Mental Health Services Administration (SAMHSA). (2024). Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. <https://www.samhsa.gov/data/report/2023-nsduh-annual-national-report>
- Saunders, H., and Rudowicz, R. (2024). A look at the latest alcohol death data and change over the last decade. KFF. <https://www.kff.org/mental-health/issue-brief/a-look-at-the-latest-alcohol-death-data-and-changes-over-the-last-decade/>
- World Health Organization (WHO). (2024). Global status report on alcohol and health and treatment of substance use disorders. Geneva. <https://www.who.int/publications/item/9789240096745>

53

ALCOHOL AND DRUG EMERGENCY DEPARTMENT VISITS

- Alcohol-related ED visits are higher than for any other substance:
 - Exceed 3.1 million in 2023, **3 times more than any other drug class.**

Top ten substances involved in drug-related ED visits, 2023

Substance	Visits (approx.)
Alcohol	3,100,000
Cannabis	1,000,000
Opioid	800,000
Methamphetamine	600,000
Drug unknown	400,000
Cocaine	300,000
Benzodiazepine	200,000
Antidepressant	150,000
Anticonvulsant	100,000
MOUD	100,000

54

MEDICATIONS FOR ALCOHOL USE DISORDER

Benefits

- Decreased Drinking
- Decreased Cravings
- Cost Effective

FDA-Approved Medications

- Acamprosate
- Naltrexone (oral and intramuscular)
- Disulfiram (not effective)

55

DISULFIRAM (ANTABUSE®): MECHANISM OF ACTION

© Elsevier, Rang et al: Pharmacology 6e - www.studentconsult.com

56

DISULFIRAM FOR ALCOHOL USE DISORDER (AUD)

- » Approved decades ago; most recent data does NOT show overwhelming efficacy*
- » Once per day dosing
- » Inhibits multiple P450 and other liver enzymes
- » Drug Interactions: benzodiazepines, phenytoin, pimozide, tricyclic antidepressants (TCAs), warfarin, sulfonylureas, metronidazole, amoxicillin, isoniazid
- » Contraindications/precautions: alcohol use, hypersensitivity to rubber, severe coronary artery disease (CAD), cirrhosis, severe renal impairment, psychosis, depression, diabetes mellitus (DM), epilepsy
- » Extensively metabolized
- » Extensive list of side effects

Source: * McPheevers M, O'Connor EA, Riley S, Kennedy SM, Voisin C, Kurnascic K, Coffey CP, Edlund MD, Bobashev G, Jonas DE. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. *JAMA*. 2023 Nov 7;330(17):1653-1665. doi: 10.1001/jama.2023.19761. PMID: 37934220; PMCID: PMC10630900.

© 2023 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

57

NALTREXONE FOR ALCOHOL USE DISORDER

- Few side effects
- Drug Interactions: opioids
- Contraindications: severe acute hepatitis
- Well studied in mild and moderate cirrhosis
- Safe in mild renal disease

© 2023 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

58

NALTREXONE EFFECTIVENESS FOR ALCOHOL USE DISORDER

- Oral naltrexone:
 - Decrease return to any drinking.
 - Decrease in return to heavy drinking.
- Long-acting injectable naltrexone:
 - Greater time to first drink.
 - Lower number of heavy drinking days.

References: McPheevers, M., et al. (2023). Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis. *JAMA*, 330(17), 1653-1665. doi: 10.1001/jama.2023.19761.
Kedia SK, Ahuja N, Dill P, Jeste A, Kumar S, Suttipapdee S. Efficacy of Extended-Release Injectable Naltrexone on Alcohol Use Disorder Treatment: A Systematic Review. *J Psychotropic Drugs*. 2023 Apr-Jun;55(2):233-245. doi: 10.1080/02791072.2022.2073300. Epub 2022 May 28.

© 2023 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

59

EXTENDED RELEASE NALTREXONE COMPARED TO OTHER AGENTS FOR ALCOHOL USE DISORDER

- » In multiple studies extended-release injectable naltrexone resulted in the following compared to oral naltrexone or other oral medications for alcohol use disorder:
 - » Longer time on medication.
 - » Decreased:
 - » Emergency department visits.
 - » Hospitalizations.
 - » Nonpharmacy costs.

References: Bryson, W. C., et al. (2011). Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization. *The American Journal of Managed Care*, 17 Suppl 8(Suppl 8), S222-S234.
Jan, S., et al. (2011). Utilization patterns of extended-release naltrexone for alcohol dependence. *The American Journal of Managed Care*, 17 Suppl 8, S210-S212.

© 2023 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

60

ACAMPROSATE: MECHANISM

In someone with an active alcohol use disorder acamprosate decreases glutamate

Glutamate Cell

Glutamate

Acamprosate

Gamma Amino Butyric Acid (GABA) cell

61

© 2020 Health Management Associates, Inc. All Rights Reserved.

ACAMPROSATE FOR ALCOHOL USE DISORDER

- » Effective
 - » Decreased quantity and frequency
 - » Increased retention in treatment and abstinence
- » Three times per day dosing
- » Drug Interactions: none
- » Contraindications: severe renal impairment
 - » Dose reduce if someone has moderate renal impairment
- » Few side effects
- » No metabolism

Photo Source: Microsoft Stock Images

62

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

BEHAVIORAL HEALTH AND MEDICATION FOR ALCOHOL USE DISORDER

Impact of Behavioral and Medication Treatment for Alcohol Use Disorder on Changes in HIV-Related Outcomes Among Patients with HIV: A Longitudinal Analysis

Kathleen A. McGinnis^a, Melissa Skanderson^a, E. Jennifer Edelman^{b,g}, Adam J. Gordon^c, P. Todd Korthuis^d, Benjamin Oldfield^b, Emily C. Williams^{e,f}, Jessica Wyse^d, Kendall Bryant^g, David A. Fiellin^{b,h}, Amy C. Justice^{a,b}, Kevin L. Kraemer^{i,j}

Medication and therapy improved HIV related outcomes

McGinnis KA, et al. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. *Drug Alcohol Depend*. 2020 Dec 1;217:108272.

© 2020 Health Management Associates, Inc. All Rights Reserved.

63

Question:

TIME FOR A POLL

Do you know anyone on medication for Alcohol Use Disorder?

A. Yes

B. No

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

64

REFERENCES: ALCOHOL USE DISORDER 1 OF 2

- Ademar K, Loftén A, Nilsson M, Domí A, Adermark L, Söderpalm B, Ericson M. Acamprosate reduces ethanol intake in the rat by a combined action of different drug components. *Sci Rep.* 2023 Oct 19;13(1):17863. doi: 10.1038/s41598-023-45167-3. PMID: 37857829; PMCID: PMC10587117.
- Higginbotham B, et al. Economic evaluations of alcohol pharmacotherapy: Systematic review of economic evaluations of pharmacotherapy for the treatment of alcohol use disorder. *Aust N Z J Psychiatry.* 2024 Feb;58(2):117-133. doi: 10.1177/00048674231201541. Epub 2023 Oct 12. PMID: 37822267; PMCID: PMC10838482.
- Jan, S., et al. (2011). Utilization patterns of extended-release naltrexone for alcohol dependence. *The American Journal of Managed Care, 17 Suppl 8, S210–S212.*
- Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. *Br J Clin Pharmacol.* 2014 Feb;77(2):315-23. doi: 10.1111/bcpt.12076. PMID: 23278595; PMCID: PMC4014018.
- Kedia SK, Ahuja N, Dillon PJ, Jones A, Kumar S, Satapathy S. Efficacy of Extended-Release Injectable Naltrexone on Alcohol Use Disorder Treatment: A Systematic Review. *J Psychoactive Drugs.* 2023 Apr-Jun;55(2):233-245. doi: 10.1080/02791072.2022.2073300. Epub 2022 May 28.
- Marin MCD, et al. Pharmacological Treatment of Alcohol Cravings. *Brain Sci.* 2023 Aug 15;13(8):1206. doi: 10.3390/brainsci13081206. PMID: 37626562; PMCID: PMC10452441.
- McGinnis KA, et al. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. *Drug Alcohol Depend.* 2020 Dec 1;217:108272.
- McPheelers M, O'Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacik K, Coffey CP, Edlund MD, Bobashev G, Jonas DE. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. *JAMA.* 2023 Nov 7;330(17):1653-1665. doi: 10.1001/jama.2023.19761. PMID: 37934220; PMCID: PMC10630900.

© 2024 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

65

REFERENCES: ALCOHOL USE DISORDER 2 OF 2

- Minnesota Department of Health. (2024) Naloxone standing order. <https://www.health.state.mn.us/communities/opioids/documents/naloxonestandingorder.pdf>
- Saunders, H., and Rudowitz, R. (2024). A look at the latest alcohol death data and change over the last decade. KFF. <https://www.kff.org/mental-health/issue-brief/a-look-at-the-latest-alcohol-death-data-and-change-over-the-last-decade/>
- Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism, Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. HHS Publication No. (SMA) 15-4907. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.
- Substance Abuse and Mental Health Services Administration (SAMHSA). (2024). Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. <https://www.samhsa.gov/data/report/2023-nsduh-annual-national-report>
- Substance Abuse and Mental Health Services Administration (SAMHSA). (2024). Drug abuse warning network: National estimates from drug-related emergency department visits, 2023. <https://www.samhsa.gov/data/sites/default/files/reports/rpt53161/dawn-national-estimates-2023.pdf>
- World Health Organization (WHO). (2024). Global status report on alcohol and health and treatment of substance use disorders. Geneva. <https://www.who.int/publications/item/9789240096745>
- Wong, J., Saver, B., Scanlan, J. M., Gianutsos, L. P., Bhakta, Y., Walsh, J., ... & Rudolf, V. (2020). The ASAM clinical practice guideline on alcohol withdrawal management. *Journal of Addiction Medicine, 14*(3S), 1-72.

© 2024 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

66

5-MINUTE STRETCH BREAK!



COUNSELING FOR CO-OCCURRING HIV & SUD

68

LEARNING OBJECTIVES:
COUNSELING FOR CO-OCCURRING HIV & SUD

Discuss coping with a HIV diagnosis and preparing patients for disclosure	Identify at least 3 considerations for mental health treatment of individuals with HIV and SUD	Distinguish acute and chronic risk of suicidality in individuals with HIV and SUD
---	--	---

© 2020 Health Management Associates, Inc. All Rights Reserved.


HEALTH MANAGEMENT ASSOCIATES

69

WHY IS IT IMPORTANT TO ADDRESS SUD IN PERSONS WITH HIV?

Substance use accelerates the progression of HIV

- » Increases viral load
- » Increases likelihood of AIDS related morbidity (even when adherent to antiretroviral medications)
- » Decreases medication adherence



Source: Dash, 2015; Schaffer 2017; Strazza 2011; Dahal 2015; Andriote 2012; NIDA 2021 <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders>

Photo Source: National Cancer Institute on Unsplash

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

70

WHY IS IT IMPORTANT TO ADDRESS SUD IN PERSONS WITH HIV?

Addictive substances weaken the blood brain barrier

- » Allowing HIV to more easily enter the brain
- » Allows infection and damage to nerves and supporting cells (glia)
- » Triggers release of neurotoxins
- » Can lead to dementia
- » 50% of people with HIV have neurocognitive disorders



Sources: Dash, 2015; Schaffer 2017; Strazza 2011; Dahal 2015; Andriote 2012; NIDA 2021 <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders>

Photo Source: Miled Fakurian on Unsplash

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

71

CURRENT SCREENING AND TESTING RATES

- » Only 38% of adults 18-64 yo in the US report ever being tested for HIV.
- » Only 76% of HIV clinics in North America reported screening HIV patients for alcohol use disorder.
- » Only 36% of HIV clinics in North America screened for other SUD.
- » Only 33% of SUD programs offer onsite HIV or HCV testing.
- » Only 49% of people with mental illness have had an HIV test.

Sources: National Institute on Drug Abuse (NIDA). (2021). Co-occurring disorders and health conditions. Lancaster KE, et al.: iDEA Consortium. (2024). Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the iDEA consortium. Int J Drug Policy, 124:104309. doi: 10.1016/j.drugpol.2023.104309.

Centers for Disease Control and Prevention (CDC)'s 2013-2023 Behavioral Risk Factor Surveillance System (BRFSS).

Substance Abuse and Mental Health Services Administration. (2023). National Substance Use and Mental Health Services Survey (N-SUMHSS) 2022: Annual Detailed Tables (SAMHSA Publication No. PEP23-07-00-002). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.

Substance Abuse and Mental Health Services Administration and Center for Disease Control and Prevention. (2024). Dear Colleague Letter Title: Advancing HIV and viral hepatitis testing with point-of-care diagnostics for people with substance use disorder.

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

72

HIV / VIRAL HEPATITIS TESTING RECOMMENDATIONS

- » SAMHSA recommends HIV/ HBV/ HCV testing:
 - » All persons >15 years of age, at least once in lifetime.
 - » Younger persons at increased risk.
 - » Anyone at high-risk test yearly.
 - » All SUD treatment programs should offer onsite same day oral fluid testing for HIV & fingerstick tests for HCV.
 - » Medicare and Medicaid pay for testing.

- People are at high risk if:
 - They share drug injection or preparation equipment
 - They have condomless sex
 - They exchange sex for drugs or money

Tests: Substance Abuse and Mental Health Services Administration (2012). *Treatment Substance Use Disorders Among People with HIV*. Advisory. CDC. <https://www.cdc.gov/phcc/susbschiv/testing/getting-tested.html> [text¹] ¹Subsidized 2007-2008; 2008-2009; 2009-2010; 2010-2011; 2011-2012; 2012-2013; 2013-2014; 2014-2015; 2015-2016; 2016-2017; 2017-2018; 2018-2019; 2019-2020; 2020-2021; 2021-2022; 2022-2023; 2023-2024; 2024-2025; 2025-2026; 2026-2027; 2027-2028; 2028-2029; 2029-2030; 2030-2031; 2031-2032; 2032-2033; 2033-2034; 2034-2035; 2035-2036; 2036-2037; 2037-2038; 2038-2039; 2039-2040; 2040-2041; 2041-2042; 2042-2043; 2043-2044; 2044-2045; 2045-2046; 2046-2047; 2047-2048; 2048-2049; 2049-2050; 2050-2051; 2051-2052; 2052-2053; 2053-2054; 2054-2055; 2055-2056; 2056-2057; 2057-2058; 2058-2059; 2059-2060; 2060-2061; 2061-2062; 2062-2063; 2063-2064; 2064-2065; 2065-2066; 2066-2067; 2067-2068; 2068-2069; 2069-2070; 2070-2071; 2071-2072; 2072-2073; 2073-2074; 2074-2075; 2075-2076; 2076-2077; 2077-2078; 2078-2079; 2079-2080; 2080-2081; 2081-2082; 2082-2083; 2083-2084; 2084-2085; 2085-2086; 2086-2087; 2087-2088; 2088-2089; 2089-2090; 2090-2091; 2091-2092; 2092-2093; 2093-2094; 2094-2095; 2095-2096; 2096-2097; 2097-2098; 2098-2099; 2099-20100; 20100-20101; 20101-20102; 20102-20103; 20103-20104; 20104-20105; 20105-20106; 20106-20107; 20107-20108; 20108-20109; 20109-20110; 20110-20111; 20111-20112; 20112-20113; 20113-20114; 20114-20115; 20115-20116; 20116-20117; 20117-20118; 20118-20119; 20119-20120; 20120-20121; 20121-20122; 20122-20123; 20123-20124; 20124-20125; 20125-20126; 20126-20127; 20127-20128; 20128-20129; 20129-20130; 20130-20131; 20131-20132; 20132-20133; 20133-20134; 20134-20135; 20135-20136; 20136-20137; 20137-20138; 20138-20139; 20139-20140; 20140-20141; 20141-20142; 20142-20143; 20143-20144; 20144-20145; 20145-20146; 20146-20147; 20147-20148; 20148-20149; 20149-20150; 20150-20151; 20151-20152; 20152-20153; 20153-20154; 20154-20155; 20155-20156; 20156-20157; 20157-20158; 20158-20159; 20159-20160; 20160-20161; 20161-20162; 20162-20163; 20163-20164; 20164-20165; 20165-20166; 20166-20167; 20167-20168; 20168-20169; 20169-20170; 20170-20171; 20171-20172; 20172-20173; 20173-20174; 20174-20175; 20175-20176; 20176-20177; 20177-20178; 20178-20179; 20179-20180; 20180-20181; 20181-20182; 20182-20183; 20183-20184; 20184-20185; 20185-20186; 20186-20187; 20187-20188; 20188-20189; 20189-20190; 20190-20191; 20191-20192; 20192-20193; 20193-20194; 20194-20195; 20195-20196; 20196-20197; 20197-20198; 20198-20199; 20199-20200; 20200-20201; 20201-20202; 20202-20203; 20203-20204; 20204-20205; 20205-20206; 20206-20207; 20207-20208; 20208-20209; 20209-20210; 20210-20211; 20211-20212; 20212-20213; 20213-20214; 20214-20215; 20215-20216; 20216-20217; 20217-20218; 20218-20219; 20219-20220; 20220-20221; 20221-20222; 20222-20223; 20223-20224; 20224-20225; 20225-20226; 20226-20227; 20227-20228; 20228-20229; 20229-20230; 20230-20231; 20231-20232; 20232-20233; 20233-20234; 20234-20235; 20235-20236; 20236-20237; 20237-20238; 20238-20239; 20239-20240; 20240-20241; 20241-20242; 20242-20243; 20243-20244; 20244-20245; 20245-20246; 20246-20247; 20247-20248; 20248-20249; 20249-20250; 20250-20251; 20251-20252; 20252-20253; 20253-20254; 20254-20255; 20255-20256; 20256-20257; 20257-20258; 20258-20259; 20259-20260; 20260-20261; 20261-20262; 20262-20263; 20263-20264; 20264-20265; 20265-20266; 20266-20267; 20267-20268; 20268-20269; 20269-20270; 20270-20271; 20271-20272; 20272-20273; 20273-20274; 20274-20275; 20275-20276; 20276-20277; 20277-20278; 20278-20279; 20279-20280; 20280-20281; 20281-20282; 20282-20283; 20283-20284; 20284-20285; 20285-20286; 20286-20287; 20287-20288; 20288-20289; 20289-20290; 20290-20291; 20291-20292; 20292-20293; 20293-20294; 20294-20295; 20295-20296; 20296-20297; 20297-20298; 20298-20299; 20299-20300; 20300-20301; 20301-20302; 20302-20303; 20303-20304; 20304-20305; 20305-20306; 20306-20307; 20307-20308; 20308-20309; 20309-20310; 20310-20311; 20311-20312; 20312-20313; 20313-20314; 20314-20315; 20315-20316; 20316-20317; 20317-20318; 20318-20319; 20319-20320; 20320-20321; 20321-20322; 20322-20323; 20323-20324; 20324-20325; 20325-20326; 20326-20327; 20327-20328; 20328-20329; 20329-20330; 20330-20331; 20331-20332; 20332-20333; 20333-20334; 20334-20335; 20335-20336; 20336-20337; 20337-20338; 20338-20339; 20339-20340; 20340-20341; 20341-20342; 20342-20343; 20343-20344; 20344-20345; 20345-20346; 20346-20347; 20347-20348; 20348-20349; 20349-20350; 20350-20351; 20351-20352; 20352-20353; 20353-20354; 20354-20355; 20355-20356; 20356-20357; 20357-20358; 20358-20359; 20359-20360; 20360-20361; 20361-20362; 20362-20363; 20363-20364; 20364-20365; 20365-20366; 20366-20367; 20367-20368; 20368-20369; 20369-20370; 20370-20371; 20371-20372; 20372-20373; 20373-20374; 20374-20375; 20375-20376; 20376-20377; 20377-20378; 20378-20379; 20379-20380; 20380-20381; 20381-20382; 20382-20383; 20383-20384; 20384-20385; 20385-20386; 20386-20387; 20387-20388; 20388-20389; 20389-20390; 20390-20391; 20391-20392; 20392-20393; 20393-20394; 20394-20395; 20395-20396; 20396-20397; 20397-20398; 20398-20399; 20399-20400; 20400-20401; 20401-20402; 20402-20403; 20403-20404; 20404-20405; 20405-20406; 20406-20407; 20407-20408; 20408-20409; 20409-20410; 20410-20411; 20411-20412; 20412-20413; 20413-20414; 20414-20415; 20415-20416; 20416-20417; 20417-20418; 20418-20419; 20419-20420; 20420-20421; 20421-20422; 20422-20423; 20423-20424; 20424-20425; 20425-20426; 20426-20427; 20427-20428; 20428-20429; 20429-20430; 20430-20431; 20431-20432; 20432-20433; 20433-20434; 20434-20435; 20435-20436; 20436-20437; 20437-20438; 20438-20439; 20439-20440; 20440-20441; 20441-20442; 20442-20443; 20443-20444; 20444-20445; 20445-20446; 20446-20447; 20447-20448; 20448-20449; 20449-20450; 20450-20451; 20451-20452; 20452-20453; 20453-20454; 20454-20455; 20455-20456; 20456-20457; 20457-20458; 20458-20459; 20459-20460; 20460-20461; 20461-20462; 20462-20463; 20463-20464; 20464-20465; 20465-20466; 20466-20467; 20467-20468; 20468-20469; 20469-20470; 20470-20471; 20471-20472; 20472-20473; 20473-20474; 20474-20475; 20475-20476; 20476-20477; 20477-20478; 20478-20479; 20479-20480; 20480-20481; 20481-20482; 20482-20483; 20483-20484; 20484-20485; 20485-20486; 20486-20487; 20487-20488; 20488-20489; 20489-20490; 20490-20491; 20491-20492; 20492-20493; 20493-20494; 20494-20495; 20495-20496; 20496-20497; 20497-20498; 20498-20499; 20499-20500; 20500-20501; 20501-20502; 20502-20503; 20503-20504; 20504-20505; 20505-20506; 20506-20507; 20507-20508; 20508-20509; 20509-20510; 20510-20511; 20511-20512; 20512-20513; 20513-20514; 20514-20515; 20515-20516; 20516-20517; 20517-20518; 20518-20519; 20519-20520; 20520-20521; 20521-20522; 20522-20523; 20523-20524; 20524-20525; 20525-20526; 20526-20527; 20527-20528; 20528-20529; 20529-20530; 20530-20531; 20531-20532; 20532-20533; 20533-20534; 20534-20535; 20535-20536; 20536-20537; 20537-20538; 20538-20539; 20539-20540; 20540-20541; 20541-20542; 20542-20543; 20543-20544; 20544-20545; 20545-20546; 20546-20547; 20547-20548; 20548-20549; 20549-20550; 20550-20551; 20551-20552; 20552-20553; 20553-20554; 20554-20555; 20555-20556; 20556-20557; 20557-20558; 20558-20559; 20559-20560; 20560-20561; 20561-20562; 20562-20563; 20563-20564; 20564-20565; 20565-20566; 20566-20567; 20567-20568; 20568-20569; 20569-20570; 20570-20571; 20571-20572; 20572-20573; 20573-20574; 20574-20575; 20575-20576; 20576-20577; 20577-20578; 20578-20579; 20579-20580; 20580-20581; 20581-20582; 20582-20583; 20583-20584; 20584-20585; 20585-20586; 20586-20587; 20587-20588; 20588-20589; 20589-20590; 20590-20591; 20591-20592; 20592-20593; 20593-20594; 20594-20595; 20595-20596; 20596-20597; 20597-20598; 20598-20599; 20599-20600; 20600-20601; 20601-20602; 20602-20603; 20603-20604; 20604-20605; 20605-20606; 20606-20607; 20607-20608; 20608-20609; 20609-20610; 20610-20611; 20611-20612; 20612-20613; 20613-20614; 20614-20615; 20615-20616; 20616-20617; 20617-20618; 20618-20619; 20619-20620; 20620-20621; 20621-20622; 20622-20623; 20623-20624; 20624-20625; 20625-20626; 20626-20627; 20627-20628; 20628-20629; 20629-20630; 20630-20631; 20631-20632; 20632-20633; 20633-20634; 20634-20635; 20635-20636; 20636-20637; 20637-20638; 20638-20639; 20639-20640; 20640-20641; 20641-20642; 20642-20643; 20643-20644; 20644-20645; 20645-20646; 20646-20647; 20647-20648; 20648-20649; 20649-20650; 20650-20651; 20651-20652; 20652-20653; 20653-20654; 20654-20655; 20655-20656; 20656-20657; 20657-20658; 20658-20659; 20659-20660; 20660-20661; 20661-20662; 20662-20663; 20663-20664; 20664-20665; 20665-20666; 20666-20667; 20667-20668; 20668-20669; 20669-20670; 20670-20671; 20671-20672; 20672-20673; 20673-20674; 20674-20675; 20675-20676; 20676-20677; 20677-20678; 20678-20679; 20679-20680; 20680-20681; 20681-20682; 20682-20683; 20683-20684; 20684-20685; 20685-20686; 20686-20687; 20687-20688; 20688-20689; 20689-20690; 20690-20691; 20691-20692; 20692-20693; 20693-20694; 20694-20695; 20695-20696; 20696-20697; 20697-20698; 20698-20699; 20699-20700; 20700-20701; 20701-20702; 20702-20703; 20703-20704; 20704-20705; 20705-20706; 20706-20707; 20707-20708; 20708-20709; 20709-20710; 20710-20711; 20711-20712; 20712-20713; 20713-20714; 20714-20715; 20715-20716; 20716-20717; 20717-20718; 20718-20719; 20719-20720; 20720-20721; 20721-20722; 20722-20723; 20723-20724; 20724-20725; 20725-20726; 20726-20727; 20727-20728; 20728-20729; 20729-20730; 20730-20731; 20731-20732; 20732-20733; 20733-20734; 20734-20735; 20735-20736; 20736-20737; 20737-20738; 20738-20739; 20739-20740; 20740-20741; 20741-20742; 20742-20743; 20743-20744; 20744-20745; 20745-20746; 20746-20747; 20747-20748; 20748-20749; 20749-20750; 20750-20751; 20751-20752; 20752-20753; 20753-20754; 20754-20755; 20755-20756; 20756-20757; 20757-20758; 20758-20759; 20759-20760; 20760-20761; 20761-20762; 20762-20763; 20763-20764; 20764-20765; 20765-20766; 20766-20767; 20767-20768; 20768-20769; 20769-20770; 20770-20771; 20771-20772; 20772-20773; 20773-20774; 20774-20775; 20775-20776; 20776-20777; 20777-20778; 20778-20779; 20779-20780; 20780-20781; 20781-20782; 20782-20783; 20783-20784; 20784-20785; 20785-20786; 20786-20787; 20787-20788; 20788-20789; 20789-20790; 20790-20791; 20791-20792; 20792-20793; 20793-20794; 20794-20795; 20795-20796; 20796-20797; 20797-20798; 20798-20799; 20799-20800; 20800-20801; 20801-20802; 20802-20803; 20803-20804; 20804-20805; 20805-20806; 20806-20807; 20807-20808; 20808-20809; 20809-20810; 20810-20811; 20811-20812; 20812-20813; 20813-20814; 20814-20815; 20815-20816; 20816-20817; 20817-20818; 20818-20819; 20819-20820; 20820-20821; 20821-20822; 20822-20823; 20823-20824; 20824-20825; 20825-20826; 20826-20827; 20827-20828; 20828-20829; 20829-20830; 20830-20831; 20831-20832; 20832-20833; 20833-20834; 20834-20835; 20835-20836; 20836-20837; 20837-20838; 20838-20839; 20839-20840; 20840-20841; 20841-20842; 20842-20843; 20843-20844; 20844-20845; 20845-20846; 20846-20847; 20847-20848; 20848-20849; 20849-20850; 20850-20851; 20851-20852; 20852-20853; 20853-20854; 20854-20855; 20855-20856; 20856-20857; 20857-20858; 20858-20859; 20859-20860; 20860-20861; 20861-20862; 20862-20863; 20863-20864; 20864-20865; 20865-20866; 20866-20867; 20867-20868; 20868-20869; 20869-20870; 20870-20871; 20871-20872; 20872-20873; 20873-20874; 20874-20875; 20875-20876; 20876-20877; 20877-20878; 20878-20879; 20879-20880; 20880-20881; 20881-20882; 20882-20883; 20883-20884; 20884-20885; 20885-20886; 20886-20887; 20887-20888; 20888-20889; 20889-20890; 20890-20891; 20891-20892; 20892-20893; 20893-20894; 20894-20895; 20895-20896; 20896-20897; 20897-20898; 20898-20899; 20899-20900; 20900-20901; 20901-20902; 20902-20903; 20903-20904; 20904-20905; 20905-20906; 20906-20907; 20907-20908; 20908-20909; 20909-20910; 20910-20911; 20911-20912; 20912-20913; 20913-20914; 20914-20915; 20915-20916; 20916-20917; 20917-20918; 20918-20919; 20919-20920; 20920-20921; 20921-20922; 20922-20923; 20923-20924; 20924-20925; 20925-20926; 20926-20927; 20927-20928; 20928-20929; 20929-20930; 20930-20931; 20931-20932; 20932-20933; 20933-20934; 20934-20935; 20935-20936; 20936-20937; 20937-20938; 20938-20939; 20939-20940; 20940-20941; 20941-20942; 20942-20943; 20943-20944; 20944-20945; 20945-20946; 20946-20947; 20947-20948; 20948-20949; 20949-20950; 20950-20951; 20951-20952; 20952-20953; 20953-20954; 20954-20955; 20955-20956; 20956-20957; 20957-20958; 20958-20959; 20959-20960; 20960-20961; 20961-20962; 20962-20963; 20963-

73

STTR MODEL OF CARE

- » Testing persons who inject drugs every 6 months is cost effective
- » **Recommendation:** Inpatient and outpatient mental health settings should offer routine opt out testing to improve case finding



Chart review compared to blood samples from 2 inpatient psychiatric units:
21% of patients with HIV positive blood samples did not have documentation of infection in medical record

HEALTH MANAGEMENT ASSOCIATE

7

TIME FOR A POLL

Question:

In your organizations, do you test for HIV?

- A. Yes
- B. No
- C. I Don't Know

EPIDEMIOLOGY- HIV & MENTAL HEALTH

- » Up to 70% of people living with HIV have a history of trauma
- » 54% of people living with HIV have post-traumatic stress disorder (PTSD)
- » People living with HIV are twice as likely to develop depressive symptoms compared to those at risk but who are not living with HIV
- » People living with HIV experience higher rates of depression than the general population
- » Key feature of depression, as compared to adjustment disorder or side effects from medication, is loss of pleasure

Sources: Kessler, R.C. 2005. Andraitx, JM. 2012. Gammie, B.N. 2008. Blank M.B. 2011.

HEALTH MANAGEMENT ASSOCIATE



EPIDEMIOLOGY- HIV & MENTAL ILLNESS

- » Twenty-two percent (22%) of people with HIV have depression
 - » Of those 78% **ALSO** have an anxiety disorder
 - » Of those 61% **ALSO** have an SUD
- » Six percent (6%) of people with HIV have schizophrenia, as compared to 1% of the general population
- » Those with schizophrenia are **1.5x** as likely to contract HIV
- » Those with affective disorders were **3.8x** as likely to contract HIV

Sources: Kessler, R.C. 2005, Andriole, JM. 2012, Gaynes, B.N. 2008, Blank M.B. 2013
 © 2018 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

77




SUD, HIV AND MENTAL ILLNESS

- » 54% people with HIV report moderate to high-risk cannabis use
- » 40% people with HIV report moderate to high-risk drinking
- » 12% people with HIV report moderate to high-risk cocaine
- » 11% people with HIV reported moderate to high risk of amphetamine use
- » Only 35% of people in 10 **outpatient** HIV clinics reported talking to primary care provider (PCP) about alcohol use
- » < 50% of providers in hospital-based HIV care programs conducted recommended screening and brief interventions for reducing alcohol

Sources: Staruss, S.M. 2009
 Andriole, JM. 2012
 Dawson Rose 2017
 © 2018 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

78



COUNSELING: COPING WITH AN HIV DIAGNOSIS

- » Coping with the diagnosis of HIV
 - » is a form of grieving
 - » is different from having a major depressive episode
 - » may require treatment
 - » support or psychotherapy
 - » will not respond to antidepressants

Sources: Andriole, JM. 2012 <http://www.aidsmap.com/news/aug-2021/hardest-outcome-all-hiv-and-suicide>
 Photo Source: LinkedIn Sales Solutions on Unsplash
 © 2018 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

79



COUNSELING RECOMMENDATIONS

1. Don't try to solve or fix things, but....
 - Housing is important
 - Social support is important
 - Medical care is important
 - These things helps establish a sense of control over one's life
2. Don't minimize someone's feelings
3. Don't tell people to pull themselves together
4. Listen... for risks and for talk of the future

Sources: Andriole, JM. 2012 <http://www.aidsmap.com/news/aug-2021/hardest-outcome-all-hiv-and-suicide>
 © 2018 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

80

CONSIDERATIONS FOR MENTAL HEALTH TREATMENT OF INDIVIDUALS WITH HIV AND SUD

- » Major Depression, among those living with HIV, responds to the same treatments:
 - » Evidence-based psychotherapy
 - » Evidence-based medications
 - » Medication and psychotherapy
- » As with other conditions, keep drug-drug interactions in mind
- » Depression & bipolar disorder can make medication adherence challenging

ANTIDEPRESSANT TREATMENT OF DEPRESSION RESULTS IN LOWER HEALTHCARE COSTS

- » Persons with bipolar disorder and HIV are more likely to have unprotected intercourse with HIV negative partners
- » The risk of suicide is higher for those with HIV (at all stages) as compared to the general population

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES Sources: McGinnis 2020, Andriote, JM. 2012 & Blank MB 2013⁸¹

SUD TREATMENT FOR THOSE LIVING WITH HIV

- » Cognitive Behavioral Therapy (CBT) & Motivational Interviewing (MI)
 - » Reduce drug use
 - » Reduce high risk sexual behaviors
 - » Reduce viral load
 - » Improve adherence to antiretrovirals

SUD Treatment is HIV Prevention!

Resources: Florida State University Center for Translational Behavioral Sciences: Tailored Motivational Interviewing and National Minority AIDS Counsel Motivational Interviewing and HIV a Guide for Navigators

Sources: National Institute on Drug Abuse (NIDA). (2021) Co-occurring disorders and health conditions. Olsner S, Patrick K, Ybarra M, Rebuck CJ, Any A, Kalishman S, Bushrui K, Barnes A, Rawson RA. Promising outcomes from a cognitive behavioral therapy text-messaging intervention targeting drug use, antiretroviral therapy adherence, and HIV risk behaviors among adults living with HIV and substance use disorders. *Drug Alcohol Depend.* 2022 Feb 1:231:109229. doi: 10.1016/j.drugalcdep.2021.109229. Epub 2021 Dec 25. PMID: 34979421. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421333/>

© 2020 Health Management Associates, Inc. All Rights Reserved.

82

SUD TREATMENT FOR THOSE LIVING WITH HIV

- » Opioid Use Disorder
 - » Methadone and buprenorphine are associated with a 54% reduction in risk of HIV infection in persons who inject drugs
- » Alcohol Use Disorder (AUD)
 - » Behavioral and medication for AUD
 - » Increase intensity of behavioral treatment led to greater improvements than lower intensity behavioral treatments among those with detectable viral loads
 - » AUDIT C scores improved
 - » Viral loads, CD4
 - » Adherence
 - » Medication for AUD was associated with
 - » Increased CD4 among those with detectable viral loads
 - » Increased adherence among those with detectable and undetectable viral loads

Source: NIDA. 2021 <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders>
McGinnis KA, et al. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. *Drug Alcohol Depend.* 2020 Dec 1:217:108272.

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES 83

EPIDEMIOLOGY- SUICIDALITY & HIV

Suicide

- » 2nd leading cause of death in 10-14 and 25-34 y.o.
- » 3rd most common cause of death in 15-24 y.o.
- » 4th leading cause of death in 35-44 y.o.
- » A life-threatening illness is one of the most strongly predictive factors for completed suicide
- » Suicide rate in those with HIV is at least twice the rate in the general population.
- » The rates of depression & suicide are greatest in the first 2 years after diagnosis but remain elevated.

Sources: National Institute of Mental Health. (2021) Suicide is one of the leading causes of death in the U.S. Cairns, G. 2021 The hardest outcome of all: HIV and suicide. AIDSMAP. Tsai YT, et al. Suicidality Among People Living With HIV From 2010 to 2021: A Systematic Review and a Meta-regression. *Psychosom Med.* 2022 Oct 1:84(8):924-939; Vollmond CV, et al. Risk of Depression in People With HIV: A Nationwide Population-based Matched Cohort Study. *Clin Infect Dis.* 2023 Nov 30;77(11):1569-1577.

Suicide Attempt Lifetime Rate

People living with HIV:
16 to 10%
General Population: 3%

Suicidal Ideation Rate

People living with HIV:
23 to 22%
General Population: 9%

© 2020 Health Management Associates, Inc. All Rights Reserved.

84

TIME FOR A POLL

Question:

People who talk about suicide, do not have attempts or complete suicide.

A. True
B. False

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

85

RISK FACTORS FOR SUICIDE

mn DEPARTMENT OF HEALTH

Suicidal Ideation Risk Assessment
STEPS AND RESOURCES FOR EXPLORING THOUGHTS OF SUICIDE

- Trauma
- Purposeless, hopeless
- Triggering event- stressor
- Poor sleep
- Ideation & past behavior
- Mood, anxiety, anger, withdrawal
- Health-medical, mental and substance
- Reckless, impulsive

Sources: <https://www.health.state.mn.us/people/syringe/suicide.pdf>

HEALTH MANAGEMENT ASSOCIATES

86

ASSESSMENT FOR SUICIDALITY

- » Which factors can be modified to reduce risk?
 - » Opportunities for healing
 - » Reduce harms
- » Protective factors
 - » Connectedness
 - » Support
 - » Skills- problem solving, coping, healing

Sources: <https://www.health.state.mn.us/people/syringe/suicide.pdf>

Photo Source: Glenn Carstens-Peters on Unsplash

HEALTH MANAGEMENT ASSOCIATES

87

ASSESSMENT RECOMMENDATIONS

1. Be mindful that protective factors are unique to each person
2. Use the person's language
3. Ask open ended questions such as:
 - » What are things that keep you safe?
 - » When this occurred in the past what has stopped you?
 - » Who are the people who lift your spirits?
 - » What activities lift your spirits?
 - » What would you like to develop within yourself in the future?
4. Try to identify protective factors that can be enhanced

Sources: <https://www.health.state.mn.us/people/syringe/suicide.pdf>

HEALTH MANAGEMENT ASSOCIATES

88

INTEGRATED PRIMARY HIV & BEHAVIORAL HEALTH CARE

Benefits of Integration

- »> Increases likelihood of follow through on referrals
- »> Improve physical health outcomes
- »> Increased savings in healthcare cost
- »> Reduce emergency room use

Ryan White HIV/AIDS Treatment Extension Act 2009

- »> Aligns with HHS guidelines
- »> Mandates include:
 1. Universal depression and SUD screening
 - »> MH screening rates currently are between 80%-100%
 - »> SUD screening rates currently are much lower
 2. Establishment of follow up plan

REFERENCES:

- Andriote, J. APA Fact Sheet HIV mental health treatment issues HIV and clinical depression 2012. Arlington VA.
- Blank MB, Himmelhoch S, Walkup J, Eisenberg MM. Treatment considerations for HIV-infected individuals with severe mental illness. *Curr HIV/AIDS Rep.* 2013 Dec;10(4):371-9.
- Branson BM, et. al. Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep.* 2006 Sep 22;55(RR-14):1-17; quiz CE1-4.
- Cairns, G. 2021 The hardest outcome of all: HIV and suicide. AIDSMAP. <https://www.aidsmap.com/news/aug-2021/hardest-outcome-all-hiv-and-suicide>
- Centers for Disease Control and Prevention (CDC)'s 2013-2023 Behavioral Risk Factor Surveillance System (BRFSS). <http://www.cdc.gov/brfss/index.html>
- Centers for Disease Control and Prevention (CDC). (2024). Fast Facts: HIV in the United States.
- Dahal S, Chitti SV, Nair MP, Saxena SK. Interactive effects of cocaine on HIV infection: implication in HIV-associated neurocognitive disorder and neuroAIDS. *Front Microbiol.* 2015 Sep 8:6931.
- Dash S, et al. Impact of cocaine abuse on HIV pathogenesis. *Front Microbiol.* 2015 Oct 20:6:1111.
- Galletly CL, Pinkerton SD, Petroll AE. CDC recommendations for opt-out testing and reactions to unanticipated HIV diagnoses. *AIDS Patient Care STDS.* 2008 Mar;22(3):189-93.
- Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. *Psychosom Med.* 2008 May;70(4):505-11.
- Glasner S, Patrick K, Ybarra M, Rebuck CJ, Ang A, Kalichman S, Bachrach K, Garneau HC, Venegas A, Rawson RA. Promising outcomes from a cognitive behavioral therapy text-messaging intervention targeting drug use, antiretroviral therapy adherence, and HIV risk behaviors among adults living with HIV and substance use disorders. *Drug Alcohol Depend.* 2022 Feb 1;231:109229.
- Hutchinson AB, Farnham PG, Sansom SL, Yajali E, Mermin JH. Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States. *J Acquir Immune Defic Syndr.* 1999; 20(1):323-330.
- Kessler RC, et.al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry.* 2005 Jun;62(6):593-602. doi: 10.1001/archpsyc.62.6.593. Erratum in: *Arch Gen Psychiatry.* 2005 Jul;62(7):768.
- Lancaster KE, et. al.; ieDEA Consortium. (2024) Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the ieDEA consortium. *Int J Drug Policy.* 124:104309. doi: 10.1016/j.drugpol.2023.104309.

REFERENCES:

- McGinnis KA, et. al. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. *Drug Alcohol Depend.* 2020 Dec 1;217:108272
- National Institute on Drug Abuse (NIDA). (2021) Co-occurring disorders and health conditions.
- National Institute on Drug Abuse (NIDA). (2025) Suicide is one of the leading causes of death in the U.S.
- Ontario HIV Network. Rapid Review #87 Effectiveness of motivational interviewing in changing risk behaviors for people living with HIV. 2014
- Rothbard AB, Blank MB, Staab JP, et al. Previously Undetected Metabolic Syndromes and Infectious Diseases Among Psychiatric Inpatients. *Psychiatric services.* 2009;60(4):534-537.
- Schaefer CP, Tome ME, Davis TP. The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. *Fluids Barriers CNS.* 2017 Nov 29;14(1):32. doi: 10.1186/s12987-017-0080-3. PMID: 29183383
- Strauss SM, Rindskopf DM. Screening patients in busy hospital-based HIV care centers for hazardous and harmful drinking patterns: the identification of an optimal screening tool. *J Int Assoc Physicians AIDS Care (Chic).* 2009 Nov-Dec;8(6):347-53. doi: 10.1177/1545109709350509. Epub 2009 Oct 22. PMID: 19850861
- Strazza M, Pirrone V, Wigdahl B, Nonnenmacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. *Brain Res.* 2011 Jul 5;1399:96-115. doi: 10.1016/j.brainres.2011.05.015. Epub 2011 May 14. PMID: 21641584
- Substance Abuse and Mental Health Services Administration and Health Resources and Services Administration, The Case for Behavioral Health Screening in HIV Care Settings. HHS Publication No. SMA-16-4993. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2016.
- Substance Abuse and Mental Health Services Administration. (2021). Treating Substance Use Disorders Among People with HIV. Advisory.
- Substance Abuse and Mental Health Services Administration. (2023). National Substance Use and Mental Health Services Survey (N-SUMHSS) 2022: Annual Detailed Tables (SAMHSA Publication No. PEP23-07-00-002). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from <https://www.samhsa.gov/data>
- Substance Abuse and Mental Health Services Administration and Center for Disease Control and Prevention. (2024) Dear Colleague Letter Title: Advancing JIV and viral hepatitis testing with point-of-care diagnostics for people with substance use disorder.
- Tsai YT, et al. Suicidality Among People Living With HIV From 2010 to 2021: A Systematic Review and a Meta-regression. *Psychosom Med.* 2022 Oct 1;64(8):924-939.
- Vollmond CV, et al. Risk of Depression in People With HIV: A Nationwide Population-based Matched Cohort Study. *Clin Infect Dis.* 2023 Nov 30;77(11):1569-1577.

STIMULANT USE

LEARNING OBJECTIVES: STIMULANT USE AND PERSONS WHO ENGAGE IN CHEMSEX

List at least 5 risks associated with methamphetamine usage	Define and identify at least 2 benefits of contingency management	Identify at least 3 risk behaviors of persons who engage in Chemsex
---	---	---

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

93

WHAT ARE STIMULANTS?

- >> Cocaine
- >> "Psychostimulants with abuse potential"
 - >> Mahuang, ephedra & khat- plants
 - >> Pseudoephedrine, ephedrine & cathinone & cathine
 - >> "Bath salts" (synthetic man made cathinones)
 - >> Amphetamine (synthetic)
 - >> Methamphetamine
 - >> Amphetamine
 - >> MDMA/ecstasy = Molly = methylenedioxy-methamphetamine
 - >> Methylphenidate = Ritalin™
 - >> Methylxanthines (naturally occurring)
 - >> Caffeine (coffee)
 - >> Theophylline (tea)
 - >> Theobromine (chocolate)



© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

94


VIOLENT CRIME ENFORCEMENT TEAMS (VCET) ARRESTS 2022 IN MINNESOTA





Drug Involved in Arrest	Number of Arrests
Cocaine	207
Methamphetamine	1426
Prescription drugs	260
Heroin	155
Synthetic narcotics	106
Heroin + synthetic narcotics	261

Office of justice programs. VCET activities and data.
<https://dps.mn.gov/divisions/ojp/ojp-grants/grant-programs/vcet-vcet>

© 2020 Health Management Associates, Inc. All Rights Reserved.

95





SOME CONSEQUENCES ARE DUE TO MODE OF CONSUMPTION

» Smoking 

- » Burned lips
- » Throat problems
- » Lung problems- acute (50% of those who smoke cocaine) and chronic 

» Injection (unsafe practices) 

- » Skin & heart infections
- » Hepatitis or HIV

» Snorting 

- » Sinus infections
- » Holes in nasal septum
- » Nosebleeds
- » Hoarseness

NOTE:
There is cross tolerance from one class of stimulants to another

© 2009 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

105

EFFECTS DEPENDENT UPON MODE OF CONSUMPTION

Drug Reaches Brain {

- Smoking- 6-8 seconds
- Injection- seconds
- Snorting- 15 minutes
- Oral-45 minutes

Half-Life {

- Cocaine .75-1.5h
- Bath Salts (Cathinone) .7-2.3 hours
- Amphetamine 7-34 hours
- Methamphetamines 6-15 hours

© 2009 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

106

TIME FOR A POLL

Question:

Have you had trouble retaining patients with stimulant use disorders in treatment?


A. Yes
B. No

© 2009 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

107

STIMULANTS EFFECTS ON BRAIN CHEMISTRY



Cocaine: Reuptake Blocker
INDIRECT agonist of

- + dopamine
- + norepinephrine
- + serotonin

BLOCKS

- + neurotransmitters reuptake
- + sodium channels

Amphetamines: Releaser
INDIRECT agonist of

- + dopamine
- + norepinephrine
- + serotonin

INHIBITS

- + metabolism of neurotransmitters
- + vesicular storage
- + reverses reuptake

Photo Source: <https://www.drugabuse.gov/news-events/nida-notes/2017/03/impacts-drugs-neurotransmission>

© 2009 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

108

ACUTE EFFECTS OF STIMULANTS

- Increased
 - Alertness/vigilance, concentration, mental acuity
 - Energy, movement
 - Sensory awareness & sexual desire
 - Self confidence, grandiosity, anxiety, irritability, paranoia
 - Heart rate & blood pressure, irregular heartbeat, vasoconstriction
 - Breathing rate, temperature, pupil size & blood sugar
 - Electrical activity, seizures
- Euphoria
- Abnormal bowel and bladder function

© 2009 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

109

- Toxic effects on muscles including
 - tremors, stereotypy (i.e., ritualistic movements)
- Decreased
 - Brain blood flow & glucose metabolism
 - Appetite & sleep
 - Judgment & complex multi-tasking
- Cardiovascular effects
 - Heart attacks
 - Arrhythmias
 - Severe hypertension
 - Strokes
- Increased potential for violence and psychosis

STIMULANT INTOXICATION: TREAT THE PRESENTING SIGN/SYMPMOT

Overdose:

Seek immediate medical attention for:

- Hypertensive (HTN) crisis
- Cardiac arrhythmias
- Heart attack
- Stroke – Act F.A.S.T.*
- Psychosis

* Facial drooping, Arm weakness, Speech difficulty, Time to call 9-1-1

Treatment of Overdose

Treat HTN with alpha and/ or beta blockers

Treat arrhythmias with anti-arrhythmics

Treat vasoconstriction with nitroglycerin

BH interventions for Overdose

Talk down the client in a calm environment

Treat agitation with benzodiazepine

Treat psychosis with antipsychotics


LONG-TERM MENTAL EFFECTS OF ILLICIT STIMULANTS

- » Tolerance to euphoria and appetite suppression
- » **Loss of ability to concentrate & severe memory loss**
- » Loss of ability to feel pleasure without drug
- » Dopamine depletion after repeated use of addictive substances to intoxication
- » Paranoia and psychosis (hallucinations & delusions)
- » Insomnia and fatigue
- » Irritability and anger
- » **Depression (suicidal ideation)**
- » Impulsive, risky sexual behavior

© 2009 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

111



LONG TERM PHYSICAL EFFECTS OF ILLICIT STIMULANTS

- » Dry mouth, severe dental decay and gum problems
- » Bruxism (tooth grinding)
- » Weight loss
- » Increased sweating; oily skin
- » Skin lesions from injection and formication (leading to skin picking)
- » Headaches
- » Movement disorders and seizures
- » **Strokes (bleeding into the brain) and heart attacks**

- » Irregular heart beats
- » Cardiomyopathy
- » Kidney and liver failure
- » Pulmonary hypertension
- » Damaged brain cells
- » Neonatal effects



STIMULANTS AND PREGNANCY

- » Pregnancy may increase risk of cardiovascular events
- » Preterm labor
- » Earlier gestational age at delivery
- » Low birth weight
- » Small for gestational age
- » Strokes in utero
- » Secreted in breast milk

Source: Gouin 2011; Kalaitzopoulos, 2018; *Smid, 2019; **Denif, 2007

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

113

Child:

Dysregulated behavior, growth, inhibitory control, attention and abstract reasoning, but these effects appear to be related to gestational age at delivery, psychiatric disorders, other prenatal exposures and quality of postnatal environment.*

Anxiety, depression at 3-year-old **

Worse cognitive function at 7-year-old **

STIMULANT USE IN PREGNANT PEOPLE

- » Pregnancy
 - » During pregnancy stimulant use is more common than opioid use
 - » Cannabis is the most used substance during pregnancy
 - » Followed by stimulants
 - » Homelessness and sexual violence predict stimulant use in women...

If Post-traumatic Stress Disorder (PTSD) is present

- » Integrated treatment is more effective for co-occurring disorder (COD)

Sources

- Center for Behavioral Health Statistics Quality. 2015 National survey on drug use and health: Detailed tables. In: 2016
- Riley, ED. Risk factors for stimulant use among homeless and unstably housed adult women. *Drug Alcohol Depend.* 2015 August 1; 153: 173–179. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4510017/pdf/nihms894947.pdf>
- Ruglass LM, Hien DA, Hu M, Campbell ANC. Associations Between Post-traumatic Stress Symptoms, Stimulant Use and Treatment Outcomes: A Secondary Analysis of NIDA's Women and Trauma Study. *Amer J on Addictions.* Vol 23(1): 80-85. Jan-Feb 2014. <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1521-0391.2013.12080.x>

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

114

CESSATION FROM STIMULANTS

- Acute withdrawal:
 - 4 days
 - No medication recommended
- Symptoms
 - Increased appetite
 - Increased sleep & dreaming
 - Decreased activity & energy
 - Depression & anhedonia
 - Decreased concentration
 - Craving

Handout: Stimulant Withdrawal: Monitoring & Treatment; available here through 5-2025
<https://addictionreeca.org/r/pnseg8rpkgg>

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

115

AMPHETAMINES AND COGNITIVE IMPAIRMENT

- » Two-thirds of people with amphetamine use disorder have cognitive impairment
- » Impairment is “associated” with:
 - » Older age
 - » Earlier onset of use
 - » Longer duration of use
 - » Greater frequency of use
- » May limit ability to follow through on treatment

- » Damage cell structures
- » Mitochondria in neurons & microglia
- » Damage DNA
- » Chromosomal alterations
- » Inflammation of microglia
- » Disruption of blood brain barrier
- » Inflammatory markers in peripheral blood
- » Cell death

Source: Paulus, M (2020) Neurobiology, clinical presentation, and treatment of methamphetamine use disorder a review. *JAMA Psychiatry* 77(9): 959-66.

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

116

AMPHETAMINES AND LINGERING EFFECTS ON BRAIN

- » May be permanent even with prolonged abstinence
 - » Attention
 - » Memory
 - » Learning efficiency
 - » Visual- spatial processing
 - » Processing speed
 - » Psychomotor speed
 - » Executive dysfunction

Cognitive Impairment
Impairs ability to engage in treatment due to trouble

- Sequencing events to get to treatment
- Remembering what is taught
- Applying what is taught

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

117

TREATMENT OF STIMULANT USE DISORDER

- » Harm Reduction
 - » Educational materials on psychological & physical effects
 - » Fentanyl & xylazine test strips
 - » Syringe Exchange/distribution & other clean injection supplies
 - » Naloxone and overdose prevention education
 - » Quiet rooms to come down
 - » Showers & antibiotics for infection prevention & treatment
 - » Condoms & info on safer sex practices
 - » Water for hydration
 - » Toothpaste and toothbrush



Photo sources:
Reproductive Health Supplies Coalition, Sara Groblechner, and Giorgio Tronato on Unsplash



118

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

TREATMENT OF STIMULANT USE DISORDER: SAMHSA EVIDENCE BASED RESOURCE GUIDE

- » Motivational Interviewing (MI)
 - » Decreased days of stimulant use & amount of stimulant used/ day
- » Cognitive Behavior Therapy (CBT)
 - » Decreased quantity of stimulant use & frequency/ week
 - » Decreased risky sexual behaviors
- » Community Reinforcement Approach- see next slide
- » Contingency Management- see next slide

**STRONG EVIDENCE FOR THESE AS INDIVIDUAL INTERVENTIONS
OR IN COMBINATION APPROACHES**

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

119

TREATMENT OF STIMULANT USE DISORDER

- » Community Reinforcement Approach (CRA)
 - » Decreased addiction severity
 - » Decreased drug use (weeks of use, frequency/week, \$/week)
 - » Increased cocaine abstinence
- » Contingency Management (CM): Strongest Effect Size
 - » Decreased
 - » days of stimulant use
 - » stimulant cravings
 - » HIV risk behaviors
 - » Studies Veterans Administration National Rollout
 - » Pre-CM: compared to 42% completed 2 sessions in 1 year
 - » Post-CM Implementation: 50% completed 14 sessions in 12 week
 - » 92% of >69,000 toxicology tests negative

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

Sources: SAMHSA
Oliva, EM (2013)
Warner & DePhillips (2020)

120

CONTINGENCY MANAGEMENT

- » Select objective target behavior (ex. abstinence)
- » Define the behaviors
 - » Abstinence from DOC? all illicit drugs? prescribed drugs? alcohol?
- » Provide immediate, consistent, tangible, desired rewards for target behavior
- » Escalate size of reward for consistent behavior
- » When target behavior does not occur
 - » Withhold the reward
 - » Reset size of reward for next occurrence of behavior
- » Example: Fishbowl Method
 - » 250 good job cards/gifts
 - » 209 vouchers for \$1; 40 for \$20; 1 for \$100

**Measure objectively & frequently
Don't set the bar too high or low**

**Reinforcement totaling \$80 = treatment as usual.
Reinforcements of \$240 improves outcomes.
Petry 2004**

SAMHSA Advisory Jan. 2025
Grant Funds up to \$750/year/patient
For CM for SUD.

121

Question:

Do you have a Contingency Management Program?

- A. Yes
- B. No
- C. I don't know

TIME FOR A POLL

WHAT TREATMENTS HAVE BEEN TRIED FOR STIMULANT USE DISORDER?

- » Cocaine & amphetamines not consistently effective
- » Antidepressants: SSRIs and tricyclic antidepressants not effective
- » Bupropion: risk of seizures; 5 failed trials for amphetamine use disorder *
- » Mirtazapine: risk of weight gain; single small study + for amphetamine use disorder in men who have sex with men
- » Treatment of co-occurring Opioid Use Disorder (OUD)
- » Opioid agonists: increased dose of buprenorphine or methadone shows decreased cocaine use generally
- » Naltrexone: + results in multiple small studies amphetamine use disorder and cocaine use disorder *
- » Antiseizure medications: Topiramate (risks); + one or two small studies in amphetamine use disorder

* See next slide

123

WHAT TREATMENTS HAVE BEEN TRIED FOR STIMULANT USE DISORDER?

https://downloads.asam.org/sitesfinity-production-blobs/docs/default-source/quality-science/stud_guideline_document_final.pdf?sfvrsn=71094b38_1

The ASAM/AAAP CLINICAL PRACTICE GUIDELINE ON THE Management of Stimulant Use Disorder



There are NO FDA approved medications for stimulant use disorders. Best Practices and Standards of Care do NOT endorse medication for stimulant disorders, by prescribers who are not experienced in addiction medicine.

124

WHAT'S ALL THE FUSS ABOUT?

- » New England Journal of Medicine article 2021
- » 400 adults with methamphetamine use disorder
- » Bupropion 450mg per day + placebo or bupropion 450mg per day + extended-release naltrexone 380mg IM q 3w (XR NTX)
- » Response defined as 3 of 4 toxicology tests negative for methamphetamines
- » 14% of patients on Bupropion + XR NTX responded vs 3% on Bupropion + placebo
- » Buprenorphine vs. placebo has a 21% difference for negative tox screen

This 6-week study has NOT been replicated yet. 11% improvement over placebo. Compare this to the EXCELLENT outcomes from psychosocial treatments.

© 2020 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
125

REFERENCES: STIMULANT USE

- ATTC Network. (2024). SAMHSA guidance for implementation of contingency management training and technical assistance - Addiction technology transfer center (ATTC) network. ATTC Network. https://attcnetwork.org/products_and_resources/samhsa-guidance-for-implementation-of-contingency-management-training-and-technical-assistance/
- Baiy, K., & London, E. D. (2007). Corticolimbic dysregulation and chronic methamphetamine abuse. *Addiction*, 102, 5–15. doi:10.1111/j.1360-0443.2006.01777.x
- Bollvar HA, Klemperer EM, Coleman SRM, DeSarno M, Skelly JM, Higgins ST. Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2021 Oct 1;78(10):1092-1102. doi: 10.1001/jamapsychiatry.2021.1969. Erratum in: *JAMA Psychiatry*. 2022 Jan 26;. PMID: 34347030; PMCID: PMC8340014.
- California Department of Public Health. (2020). California Opioid Overdose Surveillance Dashboard. <https://skylab.cdph.ca.gov/ODdash/>
- CDC/NCHS, National Vital Statistics System, Mortality. CDC WONDER, Atlanta, GA: US Department of Health and Human Services, CDC; 2020. <https://wonder.cdc.gov/>
- Chester, N., Mottram, D. R., Reilly, T., & Powell, M. (2004). Elimination of ephedrines in urine following multiple dosing: the consequences for athletes, in relation to doping control. *British journal of clinical pharmacology*, 57(1), 62–67.
- DeFilippo A, Rzeszutek MJ, Furgeson J, Ryan S, Rezania S. A smartphone-smartcard platform for contingency management in an inner-city substance use disorder outpatient program. *J Subst Abuse Treat*. 2021 Jan;120:108188. doi: 10.1016/j.jst.2020.108188. Epub 2020 Nov 2. PMID: 33298295.
- Foulds, J., & Young, J. T. (2019). Pharmacotherapy for incarcerated people with a history of violence: Response to commentary by Schofield et al. *Australian & New Zealand Journal of Psychiatry*, 54(1), 106–107. doi: 10.1177/0004867419885175
- Gouin, K., Murphy, K., & Shah, P. S. (2011). Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. *American Journal of Obstetrics and Gynecology*, 204(4), 340.e1–340.e12. doi:10.1016/j.ajog.2010.11.013
- Hedegaard H, Minino AM, Warner M. Drug overdose deaths in the United States, 1999–2017. NCHS Data Brief, no 329. Hyattsville, MD: National Center for Health Statistics; 2018.
- Hedegaard H, Minino AM, Warner M. Drug overdose deaths in the United States, 1999–2018. NCHS Data Brief, no 356. Hyattsville, MD: National Center for Health Statistics; 2020.

© 2020 Health Management Associates, Inc. All Rights Reserved.
126

REFERENCES: STIMULANT USE

- Kalaitzopoulos, D.-R., Chatzistergiou, K., Amylidi, A.-L., Kokkinidis, D. G., & Gouli, D. G. (2018). Effect of Methamphetamine Hydrochloride on Pregnancy Outcome. *Journal of Addiction Medicine*, 12(3), 220–226. doi:10.1097/adm.0000000000000391
- Lee, N. K., Jenner, L., Harney, A., & Cameron, J. (2018). Pharmacotherapy for amphetamine dependence: A systematic review. *Drug and Alcohol Dependence*. doi:10.1016/j.drugalcdep.2018.06.038
- Mayo Clinic Laboratories. (2020). Amphetamine-Type Stimulants (ATS). <https://www.mayocliniclabs.com/test-info/drug-book/amphetamine.html>
- NCHS, National Vital Statistics System. Estimates for 2019 and 2020 are based on provisional data. Estimates for 2015-2018 are based on final data (available from: https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm)
- NIDA. 2020, April 3. California: Opioid-Involved Deaths and Related Harms. Retrieved from <https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/california-opioid-involved-deaths-related-harms> on 2020, October 7
- NIHCM Foundation. (2020). Beyond Opioids: Rapid Increase in Drug Deaths Involving Stimulants. <https://www.nihcm.org/categories/beyond-opioids-rapid-increase-in-drug-deaths-involving-stimulants>
- Office of justice programs. VCET activities and data. <https://dps.mn.gov/divisions/ojp/ojp-grants/grant-programs/vcet-vcet>
- Oliva, EM, Bowe, T, Harris, A. H., & Trafton, J. A. (2013). Datapoints: False starts in psychotherapy for substance use disorders and PTSD in the VHA. *Psychiatric Services*, 64(8), 722.
- Paulus, M (2020) Neurobiology, clinical presentation, and treatment of methamphetamine use disorder a review. *JAMA Psychiatry* 77(9): 959-66.
- Peirce, JM, et al. (2006). Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study. *Archives of General Psychiatry*, 63(2), 201–208. <https://doi.org/10.1001/archpsyc.63.2.201>
- Petry N, T. J. (2004). Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? *Addiction*, 99, 349-360.

© 2020 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
127

REFERENCES: STIMULANT USE


- Sever, P. S., Dring, L. G., & Williams, R. T. (1975). The metabolism of (–)-ephedrine in man. *European Journal of Clinical Pharmacology*, 9(2-3), 193–198. doi:10.1007/bf00614017
- Smits, M. C., Metz, T. D., & Gordon, A. J. (2019). Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women. *Clinical obstetrics and gynecology*, 62(1), 168–184. <https://doi.org/10.1097/GRF.0000000000000418>
- Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment of Stimulant Use Disorders. SAMHSA Publication No. PEP20-06-01-001 Rockville, MD: National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration, 2020. <https://store.samhsa.gov/product/Treatment-of-Stimulant-Use-Disorder/PEP20-06-01-001>
- Substance Abuse and Mental Health Services Administration. (2017). Medical Review Officer Guidance Manual for Federal Workplace Drug Testing Programs. https://www.samhsa.gov/sites/default/files/workplace/mro-guidance-manual-oc2017_2.pdf
- Substance Abuse and Mental Health Services Administration. (2025). Using SAMHSA funds to implement evidence-based contingency management services. SAMHSA Publications and Digital Products. <https://library.samhsa.gov/product/using-samhsa-funds-implement-evidence-based-contingency-management-services/pep24-06-001>
- The ASAM/AAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. *Journal of Addiction Medicine* 18(1S):p 1-56, May/June 2024. | DOI: 10.1097/ADM.0000000000001299
- U.S. Drug Enforcement Administration, Division Control Division. (2019). NFLIS-Drug Special Report: Methamphetamine Reported in NFLIS, 2001–2017. Springfield, VA: U.S. Drug Enforcement Administration. <https://www.nfis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/12568NFLISdrugMethamphetamine.pdf>
- Volkow, N. D., & Morales, M. (2015). The Brain on Drugs: From Reward to Addiction. *Cell*, 162(4), 712–725. doi:10.1016/j.cell.2015.07.046
- Werner, D. D. and DePhilips, D. (2020, August 12). Contingency Management for People Experiencing Homelessness - Homeless and Housing Resource Network SAMHSA Webinar. Washington DC, Washington DC.

© 2020 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
128

CHEMSEX

129

TIME FOR A CHAT



What does the term Chemsex mean?

Type in the chat

HEALTH MANAGEMENT ASSOCIATES

130

CHEMSEX

Definition:

Chemsex (also known as sexualized drug use – SDU) is the **use of drugs to enhance sexual experience**.

Common drugs used include methamphetamine, gamma-hydroxybutyrate (GHB), gamma-butyrolactone (GBL), methylenedioxymethamphetamine (MDMA), cocaine, ketamine, poppers (amyl nitrite) or cannabis (the latter two gave rise to the term SDU).

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

131

CHEMSEX

What You Should Know:

- Chemsex is popular among some gay, bisexual, transgender, and queer persons, **but can be experienced by persons of any gender**
- Chemsex participants have higher odds of condomless anal sex with partners of different or unknown HIV status (bareback sex)
- Persons engaged in Chemsex have greater risk of acquiring sexually transmitted infections (STIs) and hepatitis C (HCV)
- Participants are at higher risk of HIV transmission
- The association with sexual risk indicates the importance of promoting harm reduction among this population (e.g., condoms, PrEP, PEP, drug knowledge).

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

132

COMMON TERMINOLOGY USED TO COMMUNICATE THE DESIRE TO ENGAGE IN CHEMSEX

Injecting	Meth	GHB	Ketamine	ChemSex
Pointing, slamming, darts	Blowing clouds, Cloudy, ice cream, tea, T, tina	Water, Gina, Swirling	K, Special K	Party, PNP, Party and play

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

133

IMPACT OF CHEMSEX DRUGS

» Engaging in chemsex can be managed by some. This can mean that there is minimal impact on an individual's general wellbeing, work, relationships with partners, friends, and family.

» For others it can prove problematic, and individuals may experience:

- impaired decision making
- it dominates social life and free time
- can lead to chaotic sexual encounters
- sexual boundaries are often crossed while high
- issues around sexual consent
- impact on sexual health: Hep C, HIV, as well as other STI's
- behaviors associated with addiction

• impact on mental health

• health issues associated with injecting drugs

• being vulnerable to mental and physical harm by others

• isolation

• unmanageable comedowns

• suicidal ideation

• an impact on work performance

• a breakdown of personal relationships

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

134

SAFER CHEMSEX

DR*GS USED DURING CHEMS*X

TOP 5 TO KNOW + SAFER USE

NATIONAL HARM REDUCTION COALITION

LIGHTHOUSE LEARNING COLLECTIVE

POPPERS

Poppers are an inhaled depressant that relaxes muscles in the body (including anal and vaginal sphincters). The effects are short-lived but felt immediately. The most common reasons for using these during sex are to relax (typically for bottoms) and to prevent cumming too quickly.

SAFER USE

- TRY TO AVOID mixing with erectile meds that help you stay hard. It can cause a lethal drop in blood pressure.
- Avoid contact with your skin and eyes. Put liquid on a cotton ball or get a sniff cap.
- Don't forget lube! Even though the muscles are relaxed, the skin around your ass or vagina can still get hurt.

© 2020 Health Management Associates, Inc. All Rights Reserved.

135

SAFER CHEMSEX

GHB/GBL (G)

G is a depressant in liquid form that's usually measured with a syringe and mixed into a drink to help mask the taste. What's called "G" can refer to GHB, GBL, 14-BD, or other similar substances—so effects can vary depending on the type and dose. The main reason for using G during sex is its ability to increase libido and sexual feelings.

SAFER USE

- Use a syringe to keep track of how much you're taking. Write it down or set an alarm.
- TRY TO AVOID using with alcohol or other depressants like benzos or antihistamines (like Benadryl) which increase risk of overdose and unconsciousness.
- Try to stay awake. Have someone put you in the recovery position if you fall asleep.
- Be mindful of physical dependence.

KETAMINE (K)

Ketamine is a white/off white powder that has both dissociative and depressive effects. It can be swallowed, snorted, or injected. The main reasons for using it during sex is that it lowers your inhibitions and improves your ability to last.

SAFER USE

- HYDRATE. K can cause a long-term health issue called ketamine bladder syndrome. Getting your fluids helps prevent it.
- Be mindful of how much you're taking. Write it down. K is stronger than cocaine, so start low and go slow.
- Plan ahead for STI + HIV prevention. Take your condoms, PEP, doxyPEP, and lube with you and communicate that it's important to you before using. When inhibitions are lower, we are more likely to take risks.

© 2020 Health Management Associates, Inc. All Rights Reserved.

136

SAFER CHEMSEX

MDMA (MOLLY/ECSTASY)

MDMA is an empathogen, which has stimulant-like effects. It usually comes as colorful pills or capsules in a variety of shapes and designs.

While pure MDMA does exist, it's important to be cautious. What's sold as MDMA can sometimes be mixed with other substances like amphetamines, ketamine, or caffeine. Many people use it to enhance pleasure, especially through touch, connection, and sensory experiences.

- Hydrate and get your electrolytes. Overheating and dehydration are possible, so drink water and have salty snacks.
- Pause between doses. Take $\frac{1}{4}$ of a pill, wait 30 minutes, and then another if you're feeling alright.
- Plan for aftercare. comedowns can last a few days
- Swallowing is better than snorting.

CRYSTAL METH (TINA)

Meth is a stimulant that can be used in a variety of ways, most commonly, boofing (booty bumping), injecting, and smoking. Meth can help get you high if you have difficulty and can boost your energy for marathon sessions.

SAFER USE

- Injecting/slammimg? Make sure to have your own syringes and works.
- Boofing/booty bumping? Make sure to watch for anal tears and have your own sterile supplies to put the d*ts inside of you. **Tip:** Use a slip syringe!
- Smoking? Make sure your pipe is sanitized with alcohol wipes and isn't broken to avoid cuts on your mouth.
- Be mindful of how much you're taking. Boofing can have stronger effects than injecting or snorting.
- TRY TO AVOID using with SSRIs or Benzos.

RESOURCES

DR*GS USED DURING CHEMS*X

SAVE THESE RESOURCES

- Dr*g dictionary: dancesafe.org
- Supply Locator + Harm Redux Info: harmreduction.org
- Chems*x Info: bhoc.me/chems
- Free chems*x support: controllingchemsex.com
- M3th-specific: tweaker.org
- S*xual health services: locator.hiv.gov
- Order a free HIV or STI home test: tmhtest.me/csaweek

NATIONAL HARM REDUCTION COALITION

LIGHTHOUSE LEARNING & COLLECTIVE

METHAMPHETAMINE AND ITS IMPACT ON HIV INFECTION

Methamphetamine use:

- Increases sexual desire, impairs judgment, and provides energy and confidence to engage in sexual activity for long periods of time (hyper-sexual)
- Causes erectile dysfunction
- Causes mucosal dryness
- Decreases adherence to HIV treatment and medical follow-up
- Increases HIV replication
- Accelerates progress of HIV-related dementia

DOES METHAMPHETAMINE ACCELERATE HIV AND HCV?


- In test tube studies, when methamphetamine is added to immune cells, it significantly increases HIV replication
 - Particularly in CD4 cells and monocytes (white blood cells)
- In mouse models, methamphetamine activated a portion of the HIV genetic code (long terminal repeat – LTR), prompting cells to release a protein tied to more rapid HIV disease progression
- The Journal of Viral Hepatitis published a study indicating that methamphetamine increases Hepatitis C replication.

Source: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675873/>

HIV AND HEPATITIS C

141

HIV AND HEPATITIS C CO-INFECTIONS



- » HIV may cause chronic HCV to advance more quickly.
- » Impact of HCV on HIV advancement is unclear.
- » In the US, between 62% - 80% of people who inject drugs who have HIV also have HCV.

Sources: HIVinfo.nih.gov. (2021). HIV and Hepatitis C. <https://hivinfo.nih.gov/understanding-hiv/facts-about-hiv-and-hepatitis-c>.
 CDC. (2020). HIV in the United States. [https://www.cdc.gov/hiv/data/research/facts-stats/index.html#:~:text=HIV%20diagnoses%20among%20people%20who%20inject%20drugs%20\(PWID\),1%2C161%20new%20HIV%20diagnoses](https://www.cdc.gov/hiv/data/research/facts-stats/index.html#:~:text=HIV%20diagnoses%20among%20people%20who%20inject%20drugs%20(PWID),1%2C161%20new%20HIV%20diagnoses).
 CDC. (2024). Fast Facts: HIV in the United States. [https://www.cdc.gov/hiv/data/research/facts-stats/index.html#:~:text=HIV%20diagnoses%20among%20people%20who%20inject%20drugs%20\(PWID\),1%2C161%20new%20HIV%20diagnoses](https://www.cdc.gov/hiv/data/research/facts-stats/index.html#:~:text=HIV%20diagnoses%20among%20people%20who%20inject%20drugs%20(PWID),1%2C161%20new%20HIV%20diagnoses).

142

HIV AND HEPATITIS C CO-INFECTIONS

- » In 2023 in Minnesota, there were 31,942 chronic cases of HCV
 - » Approximately 6,000 Co-infected with HIV and HCV
- » The U.S. Public Health Service/Infectious Diseases Society of America guidelines recommend that all HIV-infected persons be screened for HCV infection (CDC, 2014).

©2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

143

WHO SHOULD BE SCREENED FOR HCV?

- » Universal screening of all adults ≥ 18 yo, at least once.
- » All pregnant women during each pregnancy.

Periodic screening while risk factors persist:

- Persons who inject drugs and/or share needles, syringes or other drug preparation equipment.
- Persons with selected medical conditions, including receipt of hemodialysis- see next slide.

144

WHO SHOULD BE SCREENED FOR HCV CONTINUED


- » Screening regardless of age:
 - » Persons with HIV.
 - » Persons who use drugs.
 - » Persons with selected medical conditions (e.g., hemodialysis, persistently elevated ALT).
 - » Healthcare personnel post needlesticks, sharps, or mucosal exposures.
 - » Children born to mothers who are HCV+.
 - » Persons receiving blood transfusion or organ transplant before July 1992 or clotting factor concentrates before 1987.

Sources: Schillie, S., et al. (2020). CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 69(2), 1-17. <https://doi.org/10.15555/mmwr.6902a4>. Debika Bhattacharya and others. Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Clinical Infectious Diseases*, 2023; ciad319. <https://doi.org/10.1093/cid/ciad319>

145

HCV TREATMENT IN PEOPLE WHO USE DRUGS

- » Injection drug use accounts for ~ 70% of new HCV infections.
- » Active or recent drug use is **NOT** a contraindication for HCV treatment.
- » Cure rates ~ 95% in persons reporting drug use at start of HCV treatment.
- » Opioid agonist treatment (methadone or buprenorphine) reduces rate of HCV acquisition by 50%.



146

QUESTIONS?

147

NEXT STEPS

- » Join us in **two weeks** for Session 4!
- » Your registration should have included a reoccurring calendar invite for all four sessions
- » Please complete the evaluation for this session that will be sent out after via email (evaluations must be completed for those seeking CEU/CME credits).

Follow-up questions?

Contact Gabriel Velazquez at
gvelazquez@healthmanagement.com

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

148

AGENDA FOR WEBINAR SERIES

Session	Topics
#1 WEDNESDAY, NOVEMBER 5 12:00 pm to 3:00 pm	<input type="checkbox"/> Understanding HIV <input type="checkbox"/> HIV Testing, Treatment and Prevention <input type="checkbox"/> The Science of Addiction <input type="checkbox"/> Screening and Assessment
#2 WEDNESDAY, NOVEMBER 12 12:00 pm to 3:00 pm	<input type="checkbox"/> Ethical and Legal Issues <input type="checkbox"/> Funding and Policy Considerations <input type="checkbox"/> HIV Risk Reduction <input type="checkbox"/> SUD Harm Reduction <input type="checkbox"/> HIV and Stigma <input type="checkbox"/> Motivational Interviewing
#3 WEDNESDAY, NOVEMBER 19 12:00 pm to 3:00 pm	<input type="checkbox"/> Working with Persons Involved in the Legal System <input type="checkbox"/> Substance Use Disorder Treatment with Medications <input type="checkbox"/> Mental Health Treatment and Counseling <input type="checkbox"/> Stimulant Use <input type="checkbox"/> Chem Sex
#4 WEDNESDAY, DECEMBER 3 12:00 pm to 3:00 pm	<input type="checkbox"/> Cultural, Racial and Sexual Identities <input type="checkbox"/> Pregnancy and HIV, SUD/OUD <input type="checkbox"/> Accessing, Obtaining, and Integrating Services for Individuals with HIV and SUD in Minnesota

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

149

GLOSSARY OF TERMS (REVISITED)

- » Sexual orientation – a person's identity in relation to the gender or genders to which they are sexually attracted (straight, gay, lesbian, asexual, bisexual, pansexual)
- » Gender identity and/or expression - internal perception of one's gender; how one identifies or expresses oneself.
 - » Cisgender – a term used to describe a person whose gender identity aligns with those typically associated with the sex assigned to them at birth
 - » Transgender – refers to an individual whose current gender identity and/or expression differs from the sex they were assigned at birth (may have transitioned or be transitioning in how they are living)
 - » Gender Expansive - refers to an individual who expresses identity along the gender spectrum (genderqueer, gender nonconforming, nonbinary, agender, two spirit)
- » Sexual Minority – refers to a group whose sexual identity orientation or practices differ from the majority of and are marginalized by the surrounding society.

SOURCE: Centers for Educational Justice and Community Engagement, UC Berkeley

HEALTH MANAGEMENT ASSOCIATES

150

GLOSSARY OF TERMS (REVISITED)

- » Race - is usually associated with inherited physical, social and biological characteristics. In this context that means race is associated with biology. Institutionalized in a way that has profound consequences (White, African American, American Indian Alaskan Native, Native Hawaiian or Pacific Islander")
- » Ethnicity - a term used to categorize a group of people with whom you share learned characteristics and identify according to common racial, national tribal, religious, linguistic, or cultural origin or background. (Hispanic, Non-Hispanic Black, Non-Hispanic Black, etc.)

SOURCE: US Office of Management and Budget: Federal Register Vol. 62(210): 58782

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

151

COMMON ACRONYMS (REVISITED)

ART – Antiretroviral therapy	PEP – Post-exposure prophylaxis
AUD – Alcohol use disorder	PrEP – Pre-exposure prophylaxis
IDU – Injection or intravenous drug use	PLWH – Person(s) living with HIV
MSM – Men who have sex with men	PWID – Person(s) who injects drugs
OUD – Opioid use disorder	SUD – Substance use disorder
PEH – Person(s) experiencing homelessness	

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

152